Eukaryotic DNA topoisomerase II inhibitory activities of novel 2,5,6-substituted benzoxazole, benzimidazole and benzothiazole(4,5-b)pyridine derivatives. [The asterisk (*) refers to structures that are effective, according to the reference drug,
\\n\\n
IntechOpen Book Series will also publish a program of research-driven Thematic Edited Volumes that focus on specific areas and allow for a more in-depth overview of a particular subject.
\\n\\nIntechOpen Book Series will be launching regularly to offer our authors and editors exciting opportunities to publish their research Open Access. We will begin by relaunching some of our existing Book Series in this innovative book format, and will expand in 2022 into rapidly growing research fields that are driving and advancing society.
\\n\\nLaunching 2021
\\n\\nArtificial Intelligence, ISSN 2633-1403
\\n\\nVeterinary Medicine and Science, ISSN 2632-0517
\\n\\nBiochemistry, ISSN 2632-0983
\\n\\nBiomedical Engineering, ISSN 2631-5343
\\n\\nInfectious Diseases, ISSN 2631-6188
\\n\\nPhysiology (Coming Soon)
\\n\\nDentistry (Coming Soon)
\\n\\nWe invite you to explore our IntechOpen Book Series, find the right publishing program for you and reach your desired audience in record time.
\\n\\nNote: Edited in October 2021
\\n"}]',published:!0,mainMedia:{caption:"",originalUrl:"/media/original/132"}},components:[{type:"htmlEditorComponent",content:'With the desire to make book publishing more relevant for the digital age and offer innovative Open Access publishing options, we are thrilled to announce the launch of our new publishing format: IntechOpen Book Series.
\n\nDesigned to cover fast-moving research fields in rapidly expanding areas, our Book Series feature a Topic structure allowing us to present the most relevant sub-disciplines. Book Series are headed by Series Editors, and a team of Topic Editors supported by international Editorial Board members. Topics are always open for submissions, with an Annual Volume published each calendar year.
\n\nAfter a robust peer-review process, accepted works are published quickly, thanks to Online First, ensuring research is made available to the scientific community without delay.
\n\nOur innovative Book Series format brings you:
\n\nIntechOpen Book Series will also publish a program of research-driven Thematic Edited Volumes that focus on specific areas and allow for a more in-depth overview of a particular subject.
\n\nIntechOpen Book Series will be launching regularly to offer our authors and editors exciting opportunities to publish their research Open Access. We will begin by relaunching some of our existing Book Series in this innovative book format, and will expand in 2022 into rapidly growing research fields that are driving and advancing society.
\n\nLaunching 2021
\n\nArtificial Intelligence, ISSN 2633-1403
\n\nVeterinary Medicine and Science, ISSN 2632-0517
\n\nBiochemistry, ISSN 2632-0983
\n\nBiomedical Engineering, ISSN 2631-5343
\n\nInfectious Diseases, ISSN 2631-6188
\n\nPhysiology (Coming Soon)
\n\nDentistry (Coming Soon)
\n\nWe invite you to explore our IntechOpen Book Series, find the right publishing program for you and reach your desired audience in record time.
\n\nNote: Edited in October 2021
\n'}],latestNews:[{slug:"intechopen-supports-asapbio-s-new-initiative-publish-your-reviews-20220729",title:"IntechOpen Supports ASAPbio’s New Initiative Publish Your Reviews"},{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"}]},book:{item:{type:"book",id:"10",leadTitle:null,fullTitle:"Coherence and Ultrashort Pulse Laser Emission",title:"Coherence and Ultrashort Pulse Laser Emission",subtitle:null,reviewType:"peer-reviewed",abstract:"In this volume, recent contributions on coherence provide a useful perspective on the diversity of various coherent sources of emission and coherent related phenomena of current interest. These papers provide a preamble for a larger collection of contributions on ultrashort pulse laser generation and ultrashort pulse laser phenomena. Papers on ultrashort pulse phenomena include works on few cycle pulses, high-power generation, propagation in various media, to various applications of current interest. Undoubtedly, Coherence and Ultrashort Pulse Emission offers a rich and practical perspective on this rapidly evolving field.",isbn:null,printIsbn:"978-953-307-242-5",pdfIsbn:"978-953-51-4538-7",doi:"10.5772/543",price:159,priceEur:175,priceUsd:205,slug:"coherence-and-ultrashort-pulse-laser-emission",numberOfPages:700,isOpenForSubmission:!1,isInWos:1,isInBkci:!0,hash:"e1bd25a76712d1cb8792820acf2ff001",bookSignature:"F. J. Duarte",publishedDate:"December 30th 2010",coverURL:"https://cdn.intechopen.com/books/images_new/10.jpg",numberOfDownloads:88943,numberOfWosCitations:119,numberOfCrossrefCitations:38,numberOfCrossrefCitationsByBook:2,numberOfDimensionsCitations:87,numberOfDimensionsCitationsByBook:3,hasAltmetrics:1,numberOfTotalCitations:244,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"March 30th 2010",dateEndSecondStepPublish:"April 27th 2010",dateEndThirdStepPublish:"September 1st 2010",dateEndFourthStepPublish:"October 1st 2010",dateEndFifthStepPublish:"November 30th 2010",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7,8",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"13752",title:"Dr.",name:"F. J.",middleName:null,surname:"Duarte",slug:"f.-j.-duarte",fullName:"F. J. Duarte",profilePictureURL:"https://mts.intechopen.com/storage/users/13752/images/system/13752.png",biography:"F.J. Duarte is a laser physicist based in Western New York, USA. He is the author and editor of several well-known books on tunable lasers including Dye Laser Principles (Academic, New York, 1990) and Tunable Laser Optics (Elsevier Academic, New York, 2003). His most recent edited work is Tunable Laser Applications, 2nd Edition (CRC, New York, 2009).\r\nDr. Duarte has made key experimental and theoretical contributions to the field of narrow-linewidth tunable laser oscillators. These include original oscillator architectures and the generalized multiple-prism grating dispersion theory. He has also pioneered the use of Dirac’s quantum notation in the description of generalized N-slit interference and classical optics phenomena. Currently, his research focuses on further developments of dispersive narrow-linewidth laser oscillators and very large N-slit laser interferometers.\r\nDr. Duarte’s contributions are cited in some 130 laser and optics books including several classics. He received the Engineering Excellence Award from the Optical Society of America, is a Fellow of the Australian Institute of Physics, and a Fellow of the Optical Society of America.",institutionString:"Interferometric Optics",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"University of Alabama in Huntsville",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1226",title:"Optoelectronics",slug:"optics-and-lasers-optoelectronics"}],chapters:[{id:"12556",title:"Electrically-Pumped Organic-Semiconductor Coherent Emission: a Review",doi:"10.5772/13268",slug:"electrically-pumped-organic-semiconductor-coherent-emission-a-review",totalDownloads:3274,totalCrossrefCites:0,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"F. J. Duarte",downloadPdfUrl:"/chapter/pdf-download/12556",previewPdfUrl:"/chapter/pdf-preview/12556",authors:[{id:"13752",title:"Dr.",name:"F. J.",surname:"Duarte",slug:"f.-j.-duarte",fullName:"F. J. Duarte"}],corrections:null},{id:"12557",title:"Coherence of XUV Laser Sources",doi:"10.5772/13289",slug:"coherence-of-xuv-laser-sources",totalDownloads:2907,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Sebastian Roling and Helmut Zacharias",downloadPdfUrl:"/chapter/pdf-download/12557",previewPdfUrl:"/chapter/pdf-preview/12557",authors:[{id:"14275",title:"Dr.",name:"Helmut",surname:"Zacharias",slug:"helmut-zacharias",fullName:"Helmut Zacharias"}],corrections:null},{id:"12558",title:"Laser Technology for Compact, Narrow-bandwidth Gamma-ray Sources",doi:"10.5772/12998",slug:"laser-technology-for-compact-narrow-bandwidth-gamma-ray-sources",totalDownloads:3972,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Miro Shverdin, Fred Hartemann, Felicie Albert, Mike Messerly, David Gibson, Craig Siders and Chris Barty",downloadPdfUrl:"/chapter/pdf-download/12558",previewPdfUrl:"/chapter/pdf-preview/12558",authors:[{id:"13649",title:"Dr.",name:"Miro",surname:"Shverdin",slug:"miro-shverdin",fullName:"Miro Shverdin"},{id:"14313",title:"Dr.",name:"Fred",surname:"Hartemann",slug:"fred-hartemann",fullName:"Fred Hartemann"},{id:"23647",title:"Dr.",name:"Felicie",surname:"Albert",slug:"felicie-albert",fullName:"Felicie Albert"},{id:"23648",title:"Dr.",name:"Mike",surname:"Messerly",slug:"mike-messerly",fullName:"Mike Messerly"},{id:"23649",title:"Dr.",name:"David",surname:"Gibson",slug:"david-gibson",fullName:"David Gibson"},{id:"23650",title:"Dr.",name:"Craig",surname:"Siders",slug:"craig-siders",fullName:"Craig Siders"},{id:"23652",title:"Dr.",name:"Chris",surname:"Barty",slug:"chris-barty",fullName:"Chris Barty"}],corrections:null},{id:"12559",title:"Quantum Manipulations of Single Trapped-Ions beyond the Lamb-Dicke Limit",doi:"10.5772/13625",slug:"quantum-manipulations-of-single-trapped-ions-beyond-the-lamb-dicke-limit",totalDownloads:2401,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Miao Zhang and L.F. Wei",downloadPdfUrl:"/chapter/pdf-download/12559",previewPdfUrl:"/chapter/pdf-preview/12559",authors:[{id:"23983",title:"Dr.",name:"Miao",surname:"Zhang",slug:"miao-zhang",fullName:"Miao Zhang"}],corrections:null},{id:"12675",title:"Coherent Optical Phonons in Bismuth Crystal",doi:"10.5772/12901",slug:"coherent-optical-phonons-in-bismuth-crystal",totalDownloads:3114,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Davide Boschetto and Antoine Rousse",downloadPdfUrl:"/chapter/pdf-download/12675",previewPdfUrl:"/chapter/pdf-preview/12675",authors:[{id:"13438",title:"Dr.",name:"Davide",surname:"Boschetto",slug:"davide-boschetto",fullName:"Davide Boschetto"},{id:"14591",title:"Prof.",name:"Antoine",surname:"Rousse",slug:"antoine-rousse",fullName:"Antoine Rousse"}],corrections:null},{id:"12560",title:"Quantum Interference Signal from an Inhomogeneously Broadened System Excited by an Optically Phase-Controlled Laser-Pulse Pair",doi:"10.5772/13271",slug:"quantum-interference-signal-from-an-inhomogeneously-broadened-system-excited-by-an-optically-phase-c",totalDownloads:1795,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Shin-ichiro Sato and Takayuki Kiba",downloadPdfUrl:"/chapter/pdf-download/12560",previewPdfUrl:"/chapter/pdf-preview/12560",authors:[{id:"14246",title:"Prof.",name:"Shin-ichiro",surname:"Sato",slug:"shin-ichiro-sato",fullName:"Shin-ichiro Sato"}],corrections:null},{id:"12561",title:"Quantum Control of Laser-driven Chiral Molecular Motors",doi:"10.5772/13076",slug:"quantum-control-of-laser-driven-chiral-molecular-motors",totalDownloads:2392,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Masahiro Yamaki, Kunihito Hoki, Yuichi Fujimura and Sheng H. Lin",downloadPdfUrl:"/chapter/pdf-download/12561",previewPdfUrl:"/chapter/pdf-preview/12561",authors:[{id:"13778",title:"Prof.",name:"Yuichi",surname:"Fujimura",slug:"yuichi-fujimura",fullName:"Yuichi Fujimura"},{id:"13779",title:"Prof.",name:"Masahiro",surname:"Yamaki",slug:"masahiro-yamaki",fullName:"Masahiro Yamaki"},{id:"13780",title:"Prof.",name:"Kunihito",surname:"Hoki",slug:"kunihito-hoki",fullName:"Kunihito Hoki"},{id:"37785",title:"Prof.",name:"Sheng",surname:"H. Lin",slug:"sheng-h.-lin",fullName:"Sheng H. Lin"}],corrections:null},{id:"12562",title:"Energy Approach to Atoms in a Laser Filed and Quantum Dynamics with Laser Pulses of Different Shape",doi:"10.5772/13088",slug:"energy-approach-to-atoms-in-a-laser-filed-and-quantum-dynamics-with-laser-pulses-of-different-shape",totalDownloads:2116,totalCrossrefCites:3,totalDimensionsCites:5,hasAltmetrics:0,abstract:null,signatures:"Alexander Glushkov, Olga Khetselius, Andrey Svinarenko and Georgy Prepelitsa",downloadPdfUrl:"/chapter/pdf-download/12562",previewPdfUrl:"/chapter/pdf-preview/12562",authors:[{id:"13795",title:"Prof.",name:"Alexander",surname:"Glushkov",slug:"alexander-glushkov",fullName:"Alexander Glushkov"},{id:"14495",title:"Prof.",name:"Andrey",surname:"Svinarenko",slug:"andrey-svinarenko",fullName:"Andrey Svinarenko"},{id:"48675",title:"Prof.",name:"George",surname:"Prepelitsa",slug:"george-prepelitsa",fullName:"George Prepelitsa"},{id:"207215",title:"Prof.",name:"Olga",surname:"Khetselius",slug:"olga-khetselius",fullName:"Olga Khetselius"}],corrections:null},{id:"12563",title:"Second Harmonic Generation under Strong Influence of Dispersion and Cubic Nonlinearity Effects",doi:"10.5772/12868",slug:"second-harmonic-generation-under-strong-influence-of-dispersion-and-cubic-nonlinearity-effects",totalDownloads:3650,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:1,abstract:null,signatures:"Sergey Mironov, Vladimir Lozhkarev, Vladislav Ginzburg, Ivan Yakovlev, Grigory Luchinin, Efim Khazanov, Alexander Sergeev and Gerard Mourou",downloadPdfUrl:"/chapter/pdf-download/12563",previewPdfUrl:"/chapter/pdf-preview/12563",authors:[{id:"5015",title:"Prof.",name:"Efim",surname:"Khazanov",slug:"efim-khazanov",fullName:"Efim Khazanov"},{id:"13347",title:"Dr.",name:"Sergey",surname:"Mironov",slug:"sergey-mironov",fullName:"Sergey Mironov"},{id:"14449",title:"Prof.",name:"Vladimir",surname:"Lozhkarev",slug:"vladimir-lozhkarev",fullName:"Vladimir Lozhkarev"},{id:"14450",title:"Prof.",name:"Vladislav",surname:"Ginzburg",slug:"vladislav-ginzburg",fullName:"Vladislav Ginzburg"},{id:"14451",title:"Prof.",name:"Ivan",surname:"Yakovlev",slug:"ivan-yakovlev",fullName:"Ivan Yakovlev"},{id:"14452",title:"Prof.",name:"Grigory",surname:"Luchinin",slug:"grigory-luchinin",fullName:"Grigory Luchinin"},{id:"14453",title:"Prof.",name:"Alexander",surname:"Sergeev",slug:"alexander-sergeev",fullName:"Alexander Sergeev"},{id:"14454",title:"Dr.",name:"Gérard",surname:"Mourou",slug:"gerard-mourou",fullName:"Gérard Mourou"}],corrections:null},{id:"12760",title:"Temporal Stretching of Laser Pulses",doi:"10.5772/12856",slug:"temporal-stretching-of-laser-pulses",totalDownloads:6496,totalCrossrefCites:2,totalDimensionsCites:3,hasAltmetrics:1,abstract:null,signatures:"Rajeev Khare and Paritosh K. Shukla",downloadPdfUrl:"/chapter/pdf-download/12760",previewPdfUrl:"/chapter/pdf-preview/12760",authors:[{id:"13328",title:"Dr.",name:"Rajeev",surname:"Khare",slug:"rajeev-khare",fullName:"Rajeev Khare"},{id:"14363",title:"Prof.",name:"Paritosh K.",surname:"Shukla",slug:"paritosh-k.-shukla",fullName:"Paritosh K. Shukla"}],corrections:null},{id:"12564",title:"Ultrafast Laser Pulse Synchronization",doi:"10.5772/13246",slug:"ultrafast-laser-pulse-synchronization",totalDownloads:4512,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:null,signatures:"Wenxue Li, Qiang Hao, Yao Li, Ming Yan, Hui Zhou and Heping Zeng",downloadPdfUrl:"/chapter/pdf-download/12564",previewPdfUrl:"/chapter/pdf-preview/12564",authors:[{id:"14193",title:"Prof.",name:"Heping",surname:"Zeng",slug:"heping-zeng",fullName:"Heping Zeng"},{id:"14196",title:"Dr.",name:"Wenxue",surname:"Li",slug:"wenxue-li",fullName:"Wenxue Li"},{id:"14197",title:"Dr.",name:"Qiang",surname:"Hao",slug:"qiang-hao",fullName:"Qiang Hao"},{id:"14198",title:"Dr.",name:"Yao",surname:"Li",slug:"yao-li",fullName:"Yao Li"},{id:"14199",title:"Dr.",name:"Ming",surname:"Yan",slug:"ming-yan",fullName:"Ming Yan"},{id:"14200",title:"Dr.",name:"Hui",surname:"Zhou",slug:"hui-zhou",fullName:"Hui Zhou"}],corrections:null},{id:"12565",title:"Carrier-Envelope Phase Stablization of Grating Based High-Power Ultrafast Laser",doi:"10.5772/13526",slug:"carrier-envelope-phase-stablization-of-grating-based-high-power-ultrafast-laser",totalDownloads:2400,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Shouyuan Chen, Yi Wu, Kun Zhao and Zenghu Chang",downloadPdfUrl:"/chapter/pdf-download/12565",previewPdfUrl:"/chapter/pdf-preview/12565",authors:[{id:"15015",title:"Prof.",name:"Shouyuan",surname:"Chen",slug:"shouyuan-chen",fullName:"Shouyuan Chen"},{id:"15017",title:"Prof.",name:"Yi",surname:"Wu",slug:"yi-wu",fullName:"Yi Wu"},{id:"15018",title:"Dr.",name:"Kun",surname:"Zhao",slug:"kun-zhao",fullName:"Kun Zhao"},{id:"15019",title:"Prof.",name:"Zenghu",surname:"Chang",slug:"zenghu-chang",fullName:"Zenghu Chang"}],corrections:null},{id:"12566",title:"The Generation and Characterisation of Ultrashort Mid-Infrared Pulses",doi:"10.5772/13163",slug:"the-generation-and-characterisation-of-ultrashort-mid-infrared-pulses",totalDownloads:3529,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Jens Biegert, Olivier Chalus and Philip Bates",downloadPdfUrl:"/chapter/pdf-download/12566",previewPdfUrl:"/chapter/pdf-preview/12566",authors:[{id:"13988",title:"Dr.",name:"Jens",surname:"Biegert",slug:"jens-biegert",fullName:"Jens Biegert"},{id:"13989",title:"Dr.",name:"Olivier",surname:"Chalus",slug:"olivier-chalus",fullName:"Olivier Chalus"},{id:"13990",title:"Dr.",name:"Philip",surname:"Bates",slug:"philip-bates",fullName:"Philip Bates"}],corrections:null},{id:"12567",title:"Contrast Improvement of Relativistic Few-Cycle Light Pulses",doi:"10.5772/12932",slug:"contrast-improvement-of-relativistic-few-cycle-light-pulses",totalDownloads:2410,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"Laszlo Veisz",downloadPdfUrl:"/chapter/pdf-download/12567",previewPdfUrl:"/chapter/pdf-preview/12567",authors:[{id:"13500",title:"Prof.",name:"Laszlo",surname:"Veisz",slug:"laszlo-veisz",fullName:"Laszlo Veisz"}],corrections:null},{id:"12568",title:"Modeling the Interaction of a Single-Cycle Laser Pulse with a Bound Electron without Ionization",doi:"10.5772/13142",slug:"modeling-the-interaction-of-a-single-cycle-laser-pulse-with-a-bound-electron-without-ionization",totalDownloads:2052,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Ufuk Parali and Dennis Alexander",downloadPdfUrl:"/chapter/pdf-download/12568",previewPdfUrl:"/chapter/pdf-preview/12568",authors:[{id:"13269",title:"Dr.",name:"Dennis",surname:"Alexander",slug:"dennis-alexander",fullName:"Dennis Alexander"},{id:"13933",title:"Prof.",name:"Ufuk",surname:"Parali",slug:"ufuk-parali",fullName:"Ufuk Parali"}],corrections:null},{id:"12677",title:"Ultrashort, Strongly Focused Laser Pulses in Free Space",doi:"10.5772/12930",slug:"ultrashort-strongly-focused-laser-pulses-in-free-space",totalDownloads:3006,totalCrossrefCites:11,totalDimensionsCites:23,hasAltmetrics:0,abstract:null,signatures:"Alexandre April",downloadPdfUrl:"/chapter/pdf-download/12677",previewPdfUrl:"/chapter/pdf-preview/12677",authors:[{id:"13499",title:"Prof.",name:"Alexandre",surname:"April",slug:"alexandre-april",fullName:"Alexandre April"}],corrections:null},{id:"12569",title:"Interaction of Short Laser Pulses with Gases and Ionized Gases",doi:"10.5772/13102",slug:"interaction-of-short-laser-pulses-with-gases-and-ionized-gases",totalDownloads:4596,totalCrossrefCites:1,totalDimensionsCites:4,hasAltmetrics:1,abstract:null,signatures:"Stephan Brückner, Wolfgang Viöl and Stephan Wieneke",downloadPdfUrl:"/chapter/pdf-download/12569",previewPdfUrl:"/chapter/pdf-preview/12569",authors:[{id:"13598",title:"Dr.",name:"Stephan",surname:"Wieneke",slug:"stephan-wieneke",fullName:"Stephan Wieneke"},{id:"13823",title:"MSc.",name:"Stephan",surname:"Brückner",slug:"stephan-bruckner",fullName:"Stephan Brückner"},{id:"13824",title:"Dr.",name:"Wolfgang",surname:"Viöl",slug:"wolfgang-viol",fullName:"Wolfgang Viöl"}],corrections:null},{id:"12570",title:"Characterisation and Manipulation of Proton Beams Accelerated by Ultra-Short and High-Contrast Laser Pulses",doi:"10.5772/13266",slug:"characterisation-and-manipulation-of-proton-beams-accelerated-by-ultra-short-and-high-contrast-laser",totalDownloads:2867,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Sargis Ter-Avetisyan, Matthias Schnürer and Peter Victor Nickles",downloadPdfUrl:"/chapter/pdf-download/12570",previewPdfUrl:"/chapter/pdf-preview/12570",authors:[{id:"13571",title:"Dr.",name:"Sargis",surname:"Ter-Avetisyan",slug:"sargis-ter-avetisyan",fullName:"Sargis Ter-Avetisyan"},{id:"14238",title:"Dr.",name:"Matthias",surname:"Schnürer",slug:"matthias-schnurer",fullName:"Matthias Schnürer"},{id:"14239",title:"Prof.",name:"Peter Victor",surname:"Nickles",slug:"peter-victor-nickles",fullName:"Peter Victor Nickles"}],corrections:null},{id:"12571",title:"Picosecond Laser Pulse Distortion by Propagation through a Turbulent Atmosphere",doi:"10.5772/13511",slug:"picosecond-laser-pulse-distortion-by-propagation-through-a-turbulent-atmosphere",totalDownloads:3470,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Ivan Prochazka, Lukas Kral and Josef Blazej",downloadPdfUrl:"/chapter/pdf-download/12571",previewPdfUrl:"/chapter/pdf-preview/12571",authors:[{id:"14960",title:"Dr.",name:"Josef",surname:"Blazej",slug:"josef-blazej",fullName:"Josef Blazej"},{id:"14967",title:"Prof.",name:"Ivan",surname:"Prochazka",slug:"ivan-prochazka",fullName:"Ivan Prochazka"},{id:"14968",title:"Dr.",name:"Lukas",surname:"Kral",slug:"lukas-kral",fullName:"Lukas Kral"}],corrections:null},{id:"12678",title:"Comparison between Finite-Difference Time-Domain Method and Experimental Results for Femtosecond Laser Pulse Propagation",doi:"10.5772/12854",slug:"comparison-between-finite-difference-time-domain-method-and-experimental-results-for-femtosecond-las",totalDownloads:2823,totalCrossrefCites:2,totalDimensionsCites:3,hasAltmetrics:0,abstract:null,signatures:"Shinki Nakamura",downloadPdfUrl:"/chapter/pdf-download/12678",previewPdfUrl:"/chapter/pdf-preview/12678",authors:[{id:"4143",title:"Dr.",name:"Shinki",surname:"Nakamura",slug:"shinki-nakamura",fullName:"Shinki Nakamura"}],corrections:null},{id:"12572",title:"Non Perturbative Time-Dependent Density Functional Theory, TDDFT: Study of Ionization and Harmonic Generation in Linear Di-(N₂) and Tri-(CO₂, OCS, CS₂) Atomic Molecules with Ultrashort Intense Laser Pulses-Orientational Effects",doi:"10.5772/13227",slug:"non-perturbative-time-dependent-density-functional-theory-tddft-study-of-ionization-and-harmonic-gen",totalDownloads:2595,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Andre D Bandrauk and Emmanuel Penka Fowe",downloadPdfUrl:"/chapter/pdf-download/12572",previewPdfUrl:"/chapter/pdf-preview/12572",authors:[{id:"14146",title:"Dr.",name:"Andre D.",surname:"Bandrauk",slug:"andre-d.-bandrauk",fullName:"Andre D. Bandrauk"},{id:"14147",title:"Dr.",name:"Emmanuel",surname:"Penka Fowe",slug:"emmanuel-penka-fowe",fullName:"Emmanuel Penka Fowe"}],corrections:null},{id:"12679",title:"Femtosecond Fabrication of Waveguides in Ion-Doped Laser Crystals",doi:"10.5772/12885",slug:"femtosecond-fabrication-of-waveguides-in-ion-doped-laser-crystals",totalDownloads:2592,totalCrossrefCites:7,totalDimensionsCites:14,hasAltmetrics:0,abstract:null,signatures:"Andrey Okhrimchuk",downloadPdfUrl:"/chapter/pdf-download/12679",previewPdfUrl:"/chapter/pdf-preview/12679",authors:[{id:"13399",title:"Dr.",name:"Andrey",surname:"Okhrimchuk",slug:"andrey-okhrimchuk",fullName:"Andrey Okhrimchuk"}],corrections:null},{id:"12573",title:"Heat Absorption, Transport and Phase Transformation in Noble Metals Excited by Femtosecond Laser Pulses",doi:"10.5772/13211",slug:"heat-absorption-transport-and-phase-transformation-in-noble-metals-excited-by-femtosecond-laser-puls",totalDownloads:2900,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Wai-lun Chan and Robert Averback",downloadPdfUrl:"/chapter/pdf-download/12573",previewPdfUrl:"/chapter/pdf-preview/12573",authors:[{id:"14122",title:"Dr.",name:"Wai-Lun",surname:"Chan",slug:"wai-lun-chan",fullName:"Wai-Lun Chan"},{id:"14123",title:"Prof.",name:"Robert S.",surname:"Averback",slug:"robert-s.-averback",fullName:"Robert S. Averback"}],corrections:null},{id:"12574",title:"Probing Ultrafast Dynamics of Polarization Clusters in BaTiO₃ by Pulsed Soft X-Ray Laser Speckle Technique",doi:"10.5772/13379",slug:"probing-ultrafast-dynamics-of-polarization-clusters-in-batio-by-pulsed-soft-x-ray-laser-speckle-tech",totalDownloads:2343,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Kai Ji and Keiichiro Nasu",downloadPdfUrl:"/chapter/pdf-download/12574",previewPdfUrl:"/chapter/pdf-preview/12574",authors:[{id:"14564",title:"Dr.",name:"Kai",surname:"Ji",slug:"kai-ji",fullName:"Kai Ji"},{id:"14599",title:"Prof.",name:"Keiichiro",surname:"Nasu",slug:"keiichiro-nasu",fullName:"Keiichiro Nasu"}],corrections:null},{id:"12575",title:"Two-Photon Polymerization of Inorganic-Organic Hybrid Polymers as Scalable Technology Using Ultra-Short Laser Pulses",doi:"10.5772/13203",slug:"two-photon-polymerization-of-inorganic-organic-hybrid-polymers-as-scalable-technology-using-ultra-sh",totalDownloads:3467,totalCrossrefCites:7,totalDimensionsCites:18,hasAltmetrics:1,abstract:null,signatures:"Houbertz, Ruth, Steenhusen, Sönke, Stiche, Thomas1, and Sext, Gerhard",downloadPdfUrl:"/chapter/pdf-download/12575",previewPdfUrl:"/chapter/pdf-preview/12575",authors:[{id:"14099",title:"Dr.",name:"Ruth",surname:"Houbertz",slug:"ruth-houbertz",fullName:"Ruth Houbertz"}],corrections:null},{id:"12576",title:"Several Diffractive Optical Elements Fabricated by Femtosecond Laser Pulses Writing Directly",doi:"10.5772/13729",slug:"several-diffractive-optical-elements-fabricated-by-femtosecond-laser-pulses-writing-directly",totalDownloads:2684,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Zhongyi Guo, Lingling Ran, Shiliang Qu and Shutian Liu",downloadPdfUrl:"/chapter/pdf-download/12576",previewPdfUrl:"/chapter/pdf-preview/12576",authors:[{id:"15733",title:"Dr.",name:"Zhongyi",surname:"Guo",slug:"zhongyi-guo",fullName:"Zhongyi Guo"}],corrections:null},{id:"12577",title:"Sub-Wavelength Patterning of Self-Assembled Organic Monolayers via Nonlinear Processing with Femtosecond Laser Pulses",doi:"10.5772/13050",slug:"sub-wavelength-patterning-of-self-assembled-organic-monolayers-via-nonlinear-processing-with-femtose",totalDownloads:2218,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Nils Hartmann",downloadPdfUrl:"/chapter/pdf-download/12577",previewPdfUrl:"/chapter/pdf-preview/12577",authors:[{id:"13736",title:"Dr.",name:"Nils",surname:"Hartmann",slug:"nils-hartmann",fullName:"Nils Hartmann"}],corrections:null},{id:"12578",title:"Application of Short Laser Pulses",doi:"10.5772/13300",slug:"application-of-short-laser-pulses",totalDownloads:2665,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"S. Mehdi Sharifi and Abdossamad Talebpour",downloadPdfUrl:"/chapter/pdf-download/12578",previewPdfUrl:"/chapter/pdf-preview/12578",authors:[{id:"13471",title:"Dr.",name:"Seyed Mehdi",surname:"Sharifi Kalahroudi",slug:"seyed-mehdi-sharifi-kalahroudi",fullName:"Seyed Mehdi Sharifi Kalahroudi"}],corrections:null},{id:"12579",title:"Ultrashort Laser Pulses Applications",doi:"10.5772/13095",slug:"ultrashort-laser-pulses-applications",totalDownloads:3697,totalCrossrefCites:2,totalDimensionsCites:6,hasAltmetrics:0,abstract:null,signatures:"Ricardo Samad, Lilia Courrol, Sonia Baldochi and Nilson Vieira",downloadPdfUrl:"/chapter/pdf-download/12579",previewPdfUrl:"/chapter/pdf-preview/12579",authors:[{id:"13815",title:"Dr.",name:"Ricardo",surname:"Samad",slug:"ricardo-samad",fullName:"Ricardo Samad"},{id:"14327",title:"Dr.",name:"Lilia",surname:"Courol",slug:"lilia-courol",fullName:"Lilia Courol"},{id:"14328",title:"Dr.",name:"Sonia",surname:"Baldochi",slug:"sonia-baldochi",fullName:"Sonia Baldochi"},{id:"14329",title:"Dr.",name:"Nilson Dias",surname:"Vieira Junior",slug:"nilson-dias-vieira-junior",fullName:"Nilson Dias Vieira Junior"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"356",title:"Laser Pulse Phenomena and Applications",subtitle:null,isOpenForSubmission:!1,hash:"0326c656c0dd5480c2dd15d22a772d18",slug:"laser-pulse-phenomena-and-applications",bookSignature:"F. J. Duarte",coverURL:"https://cdn.intechopen.com/books/images_new/356.jpg",editedByType:"Edited by",editors:[{id:"13752",title:"Dr.",name:"F. J.",surname:"Duarte",slug:"f.-j.-duarte",fullName:"F. J. Duarte"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1505",title:"Scanning Electron Microscopy",subtitle:null,isOpenForSubmission:!1,hash:"3305b759b0efc22e8ed16e9048818817",slug:"scanning-electron-microscopy",bookSignature:"Viacheslav Kazmiruk",coverURL:"https://cdn.intechopen.com/books/images_new/1505.jpg",editedByType:"Edited by",editors:[{id:"100815",title:"Dr.",name:"Viacheslav",surname:"Kazmiruk",slug:"viacheslav-kazmiruk",fullName:"Viacheslav Kazmiruk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2397",title:"Advanced Aspects of Spectroscopy",subtitle:null,isOpenForSubmission:!1,hash:"bcc83fcd6b4bbfdaa677b37d94bdbdb6",slug:"advanced-aspects-of-spectroscopy",bookSignature:"Muhammad Akhyar Farrukh",coverURL:"https://cdn.intechopen.com/books/images_new/2397.jpg",editedByType:"Edited by",editors:[{id:"63182",title:"Dr.",name:"Muhammad Akhyar",surname:"Farrukh",slug:"muhammad-akhyar-farrukh",fullName:"Muhammad Akhyar Farrukh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2018",title:"Recent Progress in Optical Fiber Research",subtitle:null,isOpenForSubmission:!1,hash:"c9f4716122beee57c42cff13c357a2cb",slug:"recent-progress-in-optical-fiber-research",bookSignature:"Moh. Yasin, Sulaiman W. Harun and Hamzah Arof",coverURL:"https://cdn.intechopen.com/books/images_new/2018.jpg",editedByType:"Edited by",editors:[{id:"294347",title:"Dr.",name:"Moh",surname:"Yasin",slug:"moh-yasin",fullName:"Moh Yasin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2245",title:"Plasmonics",subtitle:"Principles and Applications",isOpenForSubmission:!1,hash:"e74f79681a8c87bb027f48ad33a3e068",slug:"plasmonics-principles-and-applications",bookSignature:"Ki Young Kim",coverURL:"https://cdn.intechopen.com/books/images_new/2245.jpg",editedByType:"Edited by",editors:[{id:"12009",title:"Dr.",name:"Ki Young",surname:"Kim",slug:"ki-young-kim",fullName:"Ki Young Kim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3166",title:"Optoelectronics",subtitle:"Advanced Materials and Devices",isOpenForSubmission:!1,hash:"b7263978cf34e637a4b9592eb4975f3e",slug:"optoelectronics-advanced-materials-and-devices",bookSignature:"Sergei L. Pyshkin and John M. Ballato",coverURL:"https://cdn.intechopen.com/books/images_new/3166.jpg",editedByType:"Edited by",editors:[{id:"43016",title:"Prof.",name:"Sergei",surname:"Pyshkin",slug:"sergei-pyshkin",fullName:"Sergei Pyshkin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3710",title:"Advances in Solid State Lasers",subtitle:"Development and Applications",isOpenForSubmission:!1,hash:null,slug:"advances-in-solid-state-lasers-development-and-applications",bookSignature:"Mikhail Grishin",coverURL:"https://cdn.intechopen.com/books/images_new/3710.jpg",editedByType:"Edited by",editors:[{id:"4862",title:"Mr.",name:"Mikhail",surname:"Grishin",slug:"mikhail-grishin",fullName:"Mikhail Grishin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3581",title:"Recent Optical and Photonic Technologies",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"recent-optical-and-photonic-technologies",bookSignature:"Ki Young Kim",coverURL:"https://cdn.intechopen.com/books/images_new/3581.jpg",editedByType:"Edited by",editors:[{id:"12009",title:"Dr.",name:"Ki Young",surname:"Kim",slug:"ki-young-kim",fullName:"Ki Young Kim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"256",title:"Optoelectronics",subtitle:"Materials and Techniques",isOpenForSubmission:!1,hash:"2c0d6a2a51ac114edd58f2c667297503",slug:"optoelectronics-materials-and-techniques",bookSignature:"Padmanabhan Predeep",coverURL:"https://cdn.intechopen.com/books/images_new/256.jpg",editedByType:"Edited by",editors:[{id:"36735",title:"Prof.",name:"P.",surname:"Predeep",slug:"p.-predeep",fullName:"P. Predeep"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"525",title:"Optoelectronics",subtitle:"Devices and Applications",isOpenForSubmission:!1,hash:"f444b982565b0c4be6117a35f7810047",slug:"optoelectronics-devices-and-applications",bookSignature:"Padmanabhan Predeep",coverURL:"https://cdn.intechopen.com/books/images_new/525.jpg",editedByType:"Edited by",editors:[{id:"36735",title:"Prof.",name:"P.",surname:"Predeep",slug:"p.-predeep",fullName:"P. Predeep"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"79356",slug:"corrigendum-to-nero-casertano-pig",title:"Corrigendum to: Nero Casertano Pig",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/66683.pdf",downloadPdfUrl:"/chapter/pdf-download/66683",previewPdfUrl:"/chapter/pdf-preview/66683",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/66683",risUrl:"/chapter/ris/66683",chapter:{id:"65267",slug:"nero-casertano-pig",signatures:"Riccardo Bozzi, Maurizio Gallo, Claudia Geraci,\nLuca Fontanesi and Nina Batorek-Lukač",dateSubmitted:null,dateReviewed:"December 21st 2018",datePrePublished:null,datePublished:"February 6th 2019",book:{id:"9356",title:"European Local Pig Breeds - Diversity and Performance",subtitle:"A study of project TREASURE",fullTitle:"European Local Pig Breeds - Diversity and Performance. A study of project TREASURE",slug:"european-local-pig-breeds-diversity-and-performance-a-study-of-project-treasure",publishedDate:"February 6th 2019",bookSignature:"Marjeta Candek-Potokar and Rosa M. Nieto Linan",coverURL:"https://cdn.intechopen.com/books/images_new/9356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"23161",title:"Dr.",name:"Marjeta",middleName:null,surname:"Čandek-Potokar",slug:"marjeta-candek-potokar",fullName:"Marjeta Čandek-Potokar"}],productType:{id:"3",title:"Monograph",chapterContentType:"chapter",authoredCaption:"Authored by"}},authors:[{id:"290243",title:"Dr.",name:"Riccardo",middleName:null,surname:"Bozzi",fullName:"Riccardo Bozzi",slug:"riccardo-bozzi",email:"riccardo.bozzi@unifi.it",position:null,institution:{name:"University of Florence",institutionURL:null,country:{name:"Italy"}}},{id:"292268",title:"Dr.",name:"Maurizio",middleName:null,surname:"Gallo",fullName:"Maurizio Gallo",slug:"maurizio-gallo",email:"gallo@anas.it",position:null,institution:null},{id:"292269",title:"Dr.",name:"Luca",middleName:null,surname:"Fontanesi",fullName:"Luca Fontanesi",slug:"luca-fontanesi",email:"luca.fontanesi@unibo.it",position:null,institution:null}]}},chapter:{id:"65267",slug:"nero-casertano-pig",signatures:"Riccardo Bozzi, Maurizio Gallo, Claudia Geraci,\nLuca Fontanesi and Nina Batorek-Lukač",dateSubmitted:null,dateReviewed:"December 21st 2018",datePrePublished:null,datePublished:"February 6th 2019",book:{id:"9356",title:"European Local Pig Breeds - Diversity and Performance",subtitle:"A study of project TREASURE",fullTitle:"European Local Pig Breeds - Diversity and Performance. A study of project TREASURE",slug:"european-local-pig-breeds-diversity-and-performance-a-study-of-project-treasure",publishedDate:"February 6th 2019",bookSignature:"Marjeta Candek-Potokar and Rosa M. Nieto Linan",coverURL:"https://cdn.intechopen.com/books/images_new/9356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"23161",title:"Dr.",name:"Marjeta",middleName:null,surname:"Čandek-Potokar",slug:"marjeta-candek-potokar",fullName:"Marjeta Čandek-Potokar"}],productType:{id:"3",title:"Monograph",chapterContentType:"chapter",authoredCaption:"Authored by"}},authors:[{id:"290243",title:"Dr.",name:"Riccardo",middleName:null,surname:"Bozzi",fullName:"Riccardo Bozzi",slug:"riccardo-bozzi",email:"riccardo.bozzi@unifi.it",position:null,institution:{name:"University of Florence",institutionURL:null,country:{name:"Italy"}}},{id:"292268",title:"Dr.",name:"Maurizio",middleName:null,surname:"Gallo",fullName:"Maurizio Gallo",slug:"maurizio-gallo",email:"gallo@anas.it",position:null,institution:null},{id:"292269",title:"Dr.",name:"Luca",middleName:null,surname:"Fontanesi",fullName:"Luca Fontanesi",slug:"luca-fontanesi",email:"luca.fontanesi@unibo.it",position:null,institution:null}]},book:{id:"9356",title:"European Local Pig Breeds - Diversity and Performance",subtitle:"A study of project TREASURE",fullTitle:"European Local Pig Breeds - Diversity and Performance. A study of project TREASURE",slug:"european-local-pig-breeds-diversity-and-performance-a-study-of-project-treasure",publishedDate:"February 6th 2019",bookSignature:"Marjeta Candek-Potokar and Rosa M. Nieto Linan",coverURL:"https://cdn.intechopen.com/books/images_new/9356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"23161",title:"Dr.",name:"Marjeta",middleName:null,surname:"Čandek-Potokar",slug:"marjeta-candek-potokar",fullName:"Marjeta Čandek-Potokar"}],productType:{id:"3",title:"Monograph",chapterContentType:"chapter",authoredCaption:"Authored by"}}},ofsBook:{item:{type:"book",id:"11712",leadTitle:null,title:"Hyperthyroidism - Recent Updates",subtitle:null,reviewType:"peer-reviewed",abstract:"\r\n\tHyperthyroidism is a condition caused by physiological, biological, and clinical findings, which occurs when the surrounding tissues are under the influence of high levels of hormones as a result of the excessive elevation of thyroid hormones in the blood, resulting in hypermetabolism. There is a general acceleration in metabolism. The term 'thyrotoxicosis' is sometimes used to describe this syndrome. Symptoms include nervousness, irritability, excessive sweating, increased blood pressure, and respiration, tachycardia, dyspnea, diarrhea, goiter, exophthalmos, and skin changes. Graves' disease is a very common autoimmune disease. Thyrotoxicosis presents with diffuse goiter, infiltrative ophthalmopathy, and thyroid acropathy. Antithyroid drugs, lithium carbonate, radioactive iodine, and dexamethasone are used in the treatment of hyperthyroidism. Thyrotoxicosis; is a picture characterized by hypermetabolism and hyperactivity syndrome, in which serum concentrations of T4, T3, or both are increased. Diseases that cause hyperthyroidism may originate from the thyroid gland, as well as from pituitary or non-pituitary causes. hyperthyroidism; is divided into 3 groups primary, secondary and subclinical hyperthyroidism. Primary hyperthyroidism: It may develop due to Graves' disease, TMNG, TA, and functional thyroid carcinoma metastases. Secondary hyperthyroidism: It is less common. TSH-secreting pituitary adenoma can be shaped due to thyroid hormone resistance syndrome and gestational thyrotoxicosis. Subclinical hyperthyroidism: It is a condition characterized by low TSH levels, but having serum T3 and T4 levels within normal limits.
\r\n\r\n\tThis book will provide a comprehensive overview of the causes, types, symptoms, associated diseases, and treatments of hyperthyroidism.
",isbn:"978-1-83969-982-5",printIsbn:"978-1-83969-981-8",pdfIsbn:"978-1-83969-983-2",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,isSalesforceBook:!1,isNomenclature:!1,hash:"0db49b70f29d27bc51b76ff445d85b92",bookSignature:"Dr. Volkan Gelen, Dr. Abdulsamed Kükürt and Dr. Emin Şengül",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11712.jpg",keywords:"T4, T3, TSH, Thyroid Gland, Nervousness, Graves' Disease, Goiter, Oxidative Stress, Thyrotoxicosis, Radioactive Iodine, Antioxidants, Lithium Carbonate",numberOfDownloads:3,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"May 3rd 2022",dateEndSecondStepPublish:"July 5th 2022",dateEndThirdStepPublish:"September 3rd 2022",dateEndFourthStepPublish:"November 22nd 2022",dateEndFifthStepPublish:"January 21st 2023",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"a month",secondStepPassed:!0,areRegistrationsClosed:!1,currentStepOfPublishingProcess:3,editedByType:null,kuFlag:!1,biosketch:"Dr. Volkan Gelen is a Physiology specialist who received his degree from Kafkas University, Turkey. He worked as an assistant at Atatürk University, Department of Physiology. In 2016 he joined Kafkas University as a director of the Animal Experiments Research and Application Center. He has 60 articles published in scientific journals and 20 poster presentations. His research interests include physiology, endocrine system, cancer, diabetes, cardiovascular system isolated organ bath system studies.",coeditorOneBiosketch:"Dr. Kükürt graduated from Uludağ University in Turkey. He has 27 published research articles in academic journals, 11 book chapters, and 37 papers. His research interests include biochemistry, oxidative stress, reactive species, antioxidants, lipid peroxidation, inflammation, reproductive hormones, phenolic compounds, and female infertility.",coeditorTwoBiosketch:"Dr. Emin Şengül is a Physiology specialist who received his degree from Atatürk University. He has 62 articles published in scientific journals and 20 poster presentations at scientific congresses. His research interests include physiology, endocrine system, cancer, diabetes, gastric ulcer, neurotoxicity, testicular toxicity, nephrotoxicity, cardiovascular system diseases, and isolated organ bath system studies.",coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"178366",title:"Dr.",name:"Volkan",middleName:null,surname:"Gelen",slug:"volkan-gelen",fullName:"Volkan Gelen",profilePictureURL:"https://mts.intechopen.com/storage/users/178366/images/system/178366.jpg",biography:"Volkan Gelen is a Physiology specialist who received his veterinary degree from Kafkas University in 2011. Between 2011-2015, he worked as an assistant at Atatürk University, Faculty of Veterinary Medicine, Department of Physiology. In 2016, he joined Kafkas University, Faculty of Veterinary Medicine, Department of Physiology as an assistant professor. Dr. Gelen has been engaged in various academic activities at Kafkas University since 2016. There he completed 5 projects and has 3 ongoing projects. He has 60 articles published in scientific journals and 20 poster presentations in scientific congresses. His research interests include physiology, endocrine system, cancer, diabetes, cardiovascular system diseases, and isolated organ bath system studies.",institutionString:"Kafkas University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"5",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Kafkas University",institutionURL:null,country:{name:"Turkey"}}}],coeditorOne:{id:"219081",title:"Dr.",name:"Abdulsamed",middleName:null,surname:"Kükürt",slug:"abdulsamed-kukurt",fullName:"Abdulsamed Kükürt",profilePictureURL:"https://mts.intechopen.com/storage/users/219081/images/system/219081.png",biography:"Dr. Kükürt graduated from Uludağ University in Turkey. He started his academic career as a Research Assistant in the Department of Biochemistry at Kafkas University. In 2019, he completed his Ph.D. program in the Department of Biochemistry at the Institute of Health Sciences. He is currently working at the Department of Biochemistry, Kafkas University. He has 27 published research articles in academic journals, 11 book chapters, and 37 papers. He took part in 10 academic projects. He served as a reviewer for many articles. He still serves as a member of the review board in many academic journals. He is currently working on the protective activity of phenolic compounds in disorders associated with oxidative stress and inflammation.",institutionString:null,position:null,outsideEditionCount:null,totalCites:0,totalAuthoredChapters:"6",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Kafkas University",institutionURL:null,country:{name:"Turkey"}}},coeditorTwo:{id:"456764",title:"Dr.",name:"Emin",middleName:null,surname:"Şengül",slug:"emin-sengul",fullName:"Emin Şengül",profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:"Emin SENGUL is a Physiology specialist who received his veterinary degree from Atatürk University in 2008. Between 2010-2014, he worked as an assistant at Atatürk University, Faculty of Veterinary Medicine, Department of Physiology. In 2014, he joined Atatürk University, Faculty of Veterinary Medicine, Department of Physiology as an assistant professor. Dr. Sengul has been engaged in various academic activities at Atatürk University since 2014. There are 6 completed projects and 3 ongoing projects. He has 62 articles published in scientific journals and 20 poster presentations in scientific congresses. His research interests include physiology, endocrine system, cancer, diabetes, gastric ulcer, neurotoxicity, testicular toxicity, nephrotoxicity, cardiovascular system diseases, and isolated organ bath system studies.",institutionString:"Atatürk University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Atatürk University",institutionURL:null,country:{name:"Turkey"}}},coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:[{id:"83086",title:"Therapeutic Options in Graves’ Hyperthyroidism",slug:"therapeutic-options-in-graves-hyperthyroidism",totalDownloads:3,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"184402",firstName:"Romina",lastName:"Rovan",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/184402/images/4747_n.jpg",email:"romina.r@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"872",title:"Organic Pollutants Ten Years After the Stockholm Convention",subtitle:"Environmental and Analytical Update",isOpenForSubmission:!1,hash:"f01dc7077e1d23f3d8f5454985cafa0a",slug:"organic-pollutants-ten-years-after-the-stockholm-convention-environmental-and-analytical-update",bookSignature:"Tomasz Puzyn and Aleksandra Mostrag-Szlichtyng",coverURL:"https://cdn.intechopen.com/books/images_new/872.jpg",editedByType:"Edited by",editors:[{id:"84887",title:"Dr.",name:"Tomasz",surname:"Puzyn",slug:"tomasz-puzyn",fullName:"Tomasz Puzyn"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"46653",title:"Anticancer Drug — Friend or Foe",doi:"10.5772/58552",slug:"anticancer-drug-friend-or-foe",body:'Cancer is the third most lethal disease in the world after cardiovascular, parasitic and infectious diseases, based on reports from American Cancer Society (ACS) [1,2]. In 2011, nearly 13 million people are diagnosed with cancer and hence, cancer continues to be a great threat to people now [3]. Thus, the medical needs for cancer remain one of the most demanding areas in scientific research. Several studies have been carried out to prevent and treat cancers. Chemoprevention is defined as pharmacological intervention with synthetic or naturally occurring compounds that may inhibit or prevent carcinogenesis [4]. Cancer treatment involves surgery, radiation and drugs. Surgery-the first line of therapy, is used for early stage of cancer. Radiotherapy is most often applied in a localised setting and conjunction with surgical procedures. The last one, drugs are implemented with chemotherapy (CTX), which employs a wide group of drugs that have cytotoxic effects. The anticancer drugs inhibit cell division and proliferation and are less selectivity towards cancer cells. Thus, these drugs not only destroy cancer cells but also destroy normal cells.
In this chapter “Anti Cancer Drug: Friend or Foe” we have evaluated the beneficial and harmful effects of anticancer drugs.
Anticancer or chemotherapy drugs are chemicals that can denature cancer cells by arresting their growth. Though anticancer drugs affect dividing cancer cells, normal cells are also affected in the course of the event. The most affected cells are:
In addition to the above organs, liver and kidneys (slow proliferating cells) are affected since they are the organs of metabolism or target organs of toxicity.
Today, more than 100 different drugs have been used for chemotherapy, either alone or in combination with other treatments. For several years, the most effective drugs used in chemotherapy were considered to be DNA damaging agents [5]. These drugs can be divided into different categories based on their mechanism of action. They are summarized in Figure 1.
Classification of anticancer drugs.
This class of drugs directly damages DNA by adding methyl or other alkyl groups onto nucleotide bases [6] and thereby inhibit their correct utilization by base pairing leading to mutation, DNA fragmentation as well as inhibition of DNA replication and transcription. They also disrupt cell respiration and intermediary metabolism by alkylation of proteins and enzymes. The anticancer drugs that contain alkylating agents are
Family of alkylating agents.
Inhibitors of DNA synthesis inhibit essential biosynthetic processes or are incorporated into DNA, RNA, proteins and other macromolecules. These drugs (Figure 3) are either structural analogues for heterocyclic bases or agents interfering with folate metabolism. DNA building blocks include heterocyclic bases and folic acid. They inhibit main steps in the formation of purine and pyrimidine bases as well as nucleotides [7]. This class of drugs includes antifolates (
Anti-metabolites.
Antitumor antibiotics and topoisomerase inhibitors are obtained from the cultures of various microorganisms. Examples:
Furthermore, topoisomerase inhibitors have been used to interfere with the action of topoisomerase I and II enzymes. These enzymes regulate the changes in DNA structure which includes DNA replication, transcription, recombination, and chromatin remodelling [10-15]. The important inhibitors are
Structure of DNA-Topoisomerase II.
Bi-and ter-benzimidazole derivatives constitute a new class of DNA Topo I and II inhibitors [16-20]. In addition, a camptothecin derivative with a benzoxazole ring is shown significantly more potent than camptothecin as an inhibitor of DNA Topo I [21]. It is of the opinion that a fused ring system in the chemical structure is critical and important for the biological activity. For example, 2-(4-aminophenyl)benzothiazoles, are observed by Shi et al. [22], exhibit potent anti-tumour activity against some cell lines (breast, ovarian, colon, and renal cell lines). Choi et al. [23] also synthesized a series of 2-(4-aminophenyl)benzothiazole and evaluated the Topo II inhibitory activity.
There are studies on the inhibitory effects of some novel fused heterocyclic compounds, (
The structure of the reference drug-etoposide.
Eukaryotic DNA topoisomerase II inhibitory activities of novel 2,5,6-substituted benzoxazole, benzimidazole and benzothiazole(4,5-b)pyridine derivatives. [The asterisk (*) refers to structures that are effective, according to the reference drug,
Other examples are:
Hormone antagonists are used for tumors caused by hormones or hormonal imbalance. Examples:
The endogenous estrogens in women are steroid hormones. Possible consequences of the lack of estrogen in postmenopausal women are frequently reported, including postmenopausal symptoms, increased risks of osteoporosis, coronary heart disease and Alzheimer\'s disease [29-33]. On the other hand, the cumulative exposure to estrogen encourages development of female reproductive cancers. Such examples include breast cancer and uterus cancer, which are found associated with hormone replacement therapy, early menarche and late menopause [34]. The contribution of estrogens in various physiological and pathological pathways depends on the binding to estrogen receptors. It also activates transcription of estrogen responsive genes [35-38].
The anti-cancer drug
Relative Binding Activities (RBA) of 11-Alkyl–6,11-dihydrohydroxy-5H-benzo [α]carbazoles [39].
Furthermore, the X-ray structure of 17
Estradiol (green) superimposed on compound
Medicines that are used as anticancer drugs are:
Many of the CTX drugs that are employed are naturally occurring compounds extracted from plants, while others are synthetic. Genotoxic agents bind to DNA and directly and/or indirectly affect the replication which induces the apoptosis. These agents are also divided into three important subunits-alkylating agents, intercalating agents and enzyme inhibitors. Etoposide is an enzyme inhibitor which inhibits topoisomerase II and prevents resealing of DNA that leads to cell death. However, this drug structure exhibits undesired effect for treatment of the disease. Due to this reason, different methods have been improved to evaluate the adverse effects of etoposide, the most effective and potent drug.
There are two approaches to evaluate the adverse effects of the potent drugs-first one, is synthetic way. Researchers try to find derivatives of this drug agent with the conventional way. In the another approach, they use novel and rational drug design, discovery and development methods which are more economic and minimize time and labor by using computer models, compared with the usual conventional methods.
An understanding of toxicity or adverse effects of anticancer compounds is important to design effective and potent drug combinations and also to interpret toxicological profile of new chemical entities. Most cytotoxic anticancer agents are evaluated at the maximum tolerated dose levels. The toxicity of these compounds is often a manifestation of their mechanism of action and their effect on growing normal cells such as
Bone marrow depression due to damage for the growing stem cells causes a reduction in the white blood cell, platelet, and red cell counts. These, in turn, could cause susceptibility to infections, excessive bleeding, and anemia. In addition, certain drugs cause unique and severe bone damage, such as the osteonecrosis of the jaw associated with bisphosphonates [40].
Damage to growing cells may cause temporary loss of hair (alopecia), skin rashes, changes in the color and texture, or loss of fingernails and toenails. These toxicities are usually reversible.
Surface epithelial damage to the gastrointestinal tract may result in ulcers, stomatitis, difficulty in swallowing (dysphagia), vulnerability to oral infections such as candidiasis, and changes in saliva secretion. In addition, nausea, vomiting, diarrhea, or constipation occur commonly.
Some drugs may cause kidney damage due to extensive cell destruction, purine catabolism, and deposition of urates in the renal tubules. The activity of drugs depends on the individual physiological system and the mode of renal handling of drugs.
Cinnamaldehyde (an anticancer drug) at a dose level of 73.5 mg / kg body weight / day induced histopathological changes of kidney accompanied by increased activity of marker enzymes and an imbalance in the antioxidant status, in rats. Cinnamaldehyde induced renal damage, is due to the reactive oxygen species that formed while in the free radical scavenging reactions [41-43].
In addition, liver damage may occur due to large blood supply. Metabolic conditions of the liver and the kidney are usually monitored for possible correlation to drug levels in the blood and dosage adjustments, since these are the major drug elimination sites or the target organs of toxicity.
Certain symptoms and adverse effects associated with cancer could be secondary to disease progression. For example, cancer metastases to the bones could cause chronic pain due to the proliferation of cancer cells in the bones and the associated bone remodeling and destruction. Also, tumors that compress veins, the use of central vein catheter, and relative immobility of the patient could lead to deep vein thrombosis with potential pulmonary embolism [44-46].
Drugs such as paclitaxel and vincristine could cause peripheral neuropathy. Similarly, anthracyclines are known for rare but severe cardiotoxicity [47-49].
Thus, adverse effect and dose-limiting toxicity of anticancer compounds could be a manifestation of either their mechanisms of action or unrelated toxicities common to a given chemical entity of compounds (anthracyclines and etoposide). A close attention to monitor the emergence of known side effects of anticancer drugs, as well as those observed in the preclinical animal toxicology studies, ensures patient safety in early oncology drug clinical trials.
Especially, chemotherapy has been integrated into treatment programs with surgery and radiation therapy. The major problem of the clinical efficacy in chemotherapy is because of toxicity of the anticancer drugs to the normal tissues of the body. Rapidly proliferating tissues such as bone marrow, gastrointestinal tract, hair follicle, etc are the major sites of acute toxicities. In addition, chronic and cumulative toxicities may also occur. There are measures and agents which can improve the toxicities of anticancer drugs. Furthermore, current challenges of anticancer drug development include the significant time and cost involvement, and the low success rates. These issues lead to increasing efforts of the pharmaceutical industry toward increasing the effectiveness of the drug discovery and development process to minimize failure of drug candidates at later stages of development. It also includes development of high throughput preclinical screening methods (computational molecular modeling techniques) and biological assays with greater specificity and predictability.
Increasing emphasis is being placed on developing a mechanistic understanding of the physicochemical and biological phenomena involved in drug development such as chemical structure and polymorph stability, and pharmacokinetics. The use of mathematical models to explain the mechanisms of drug degradation and predict the outcomes of formulation and process changes and scale-up is increasingly being adopted such as Quantitative Structure Activity Relationships (QSAR). This chapter summarises the beneficial and harmful (toxicity) effects of anticancer drugs and other measures adopted for its management. Proper handling of anticancer agents is the utmost importance at the earlier phase because it has an affiliation with the course of treatment and outcome of the patient in his physical, mental and social wellbeing. Because of these reasons, computer aided drug design and discovery are used to reduce the side effects of the anticancer drugs. These procedures result in effective therapeutic options for chemotherapy.
On general consideration, antioxidants (vitamins) play a significant role to ameliorate the toxicity. Thus, fruits and vegetables in the diet might protect human health from toxic effects of drugs at certain extent [50]. While in chemotherapy, if the patients are given vitamin rich food (vegetables, fruits, etc), then toxicity of the chemotherapeutic drugs can be prevented at certain extent.
Chronic myeloproliferative disorders are a group of clonal diseases of the stem cell. It is a group of several diseases with some common features. They derive from a multipotential hematopoietic stem cell. A clone of neoplastic cells in all these neoplams is characterized by a lower proliferative activity than that of acute myeloproliferative diseases. In each of these diseases, leukocytosis, thrombocythemia, and polyglobulia may appear at some stage, depending on the diagnosis [1, 2].
The research on interferon has been going on since the 1950s [3]. Then, the attention was paid to its influence on the immune system. It has been noted that it can exert an antiproliferative effect by stimulating cells of the immune system [4]. In 1987, a publication by Ludwig et al. was published, which reported the effectiveness of interferon alpha in the treatment of chronic myeloproliferative disorders [5].
More and more new studies have been showing the effectiveness of interferon alpha in reducing the number of platelets, reducing the need for phlebotomies in patients with polycythemia vera and also in reducing the number of leukocytes. Moreover, interferon reduced the symptoms of myeloproliferative disorders such as redness and itching of the skin. Additionally, it turned out to be effective in reducing the size of the spleen.
Further studies on the assessment of remission using molecular-level response assessments indicate that the interferon action in chronic myeloproliferation diseases targets cells from the mutant clone with no effect on normal bone marrow cells [6].
Over the years, interferon alpha-2a and interferon alpha-2b have been introduced into the treatment of chronic myeloproliferation, followed by their pegylated forms. The introduction of pegylated forms allowed for a reduction in the number of side effects and less frequent administration of the drug to patients. In recent years, monopegylated interferon alpha-2b has been used to further increase the interval between drug administrations while maintaining its antiproliferative efficacy.
The exact mechanism of action of interferon alpha in the treatment of chronic myeloproliferative disease is still not fully understood, but it has an impact on JAK2 (Janus Kinase) signal transducers and activates the STAT signal pathway (Janus Kinase/SignalTransducer and Activator of Transcription).
Interferon alpha binds to IFNAR1 and IFNAR2c, which are type I interferon receptors. Interferon alpha has an impact on JAK2(Janus Kinase) signal transducers and activates the STAT signal pathway. The disturbances in this signaling pathway are observed in chronic myeloproliferative disorders [7].
Interferon inhibits the JAK-STAT signaling pathway by directly inhibiting the action of thrombopoietin in this pathway [8].
So far, three driver mutations have been described in the course of chronic myeloproliferative diseases that affect the functioning of the JAK-STAT pathway.
JAK2 kinase and JAK1, JAK3, and TYK2 kinases belong to the family of non-receptor tyrosine kinases. They are involved in the intracellular signal transduction of the JAK-STAT pathway. It is a system of intracellular proteins used by growth factors and cytokines to express genes that regulate cell activation, proliferation, and differentiation. The mechanism of JAK activation is based on the autophosphorylation of tyrosine residues that occurs after ligand binds to the receptor. JAK2 kinase transmits signals from the hematopoietic cytokine receptors of the myeloid lineage (erythropoietin, granulocyte-colony stimulating factor thrombopoietin, and lymphoid lineage [9].
A somatic G/T point mutation in exon 14 of the JAK2 kinase gene converts valine to phenylalanine at position 617 (V617F) in the JAK2 pseudokinase domain, which allows constitutive, ligand-independent activation of the receptor to trigger a proliferative signal [10].
Mutation of the MPL gene, which encodes the receptor for thrombopoietin, increases the sensitivity of magekaryocytes to the action of thrombopoietin, which stimulates their proliferation [11].
Malfunction of calreticulin as a result of mutation of the CARL gene leads to the activation of the MPL-JAK/STAT signaling pathway, which is independent of the ligand, as calreticulin is responsible, for the proper formation of the MPL receptor. Consequently, there is a clonal proliferation of hematopoietic stem cells [12].
Below, we provide an overview of some clinical studies on the efficacy of interferon in chronic myeloproliferative disorders.
Polycythemia vera (PV) is characterized by an increase in the number of erythrocytes in the peripheral blood.
Polycythemia vera is caused by a clonal mutation in the multipotential hematopoietic stem cell of the bone marrow. The mutation leads to an uncontrolled proliferation of the mutated cell clone, independent of erythropoietin and other regulatory factors. As the mutation takes place at an early stage of hematopoiesis, an increase of the number of erythrocytes as well as of leukocytes and platelets is observed in the peripheral blood. The cause of proliferation in PV independent from external factors is a mutation in the Janus 2 (JAK2) tyrosine kinase gene. The V617F point mutation in the JAK2 gene is responsible for about 96% mutation, and in the remaining cases the mutation arises in exon 12. Both mutations lead to constitutive activation of the JAK-STAT signaling pathway [13].
As a result of the uncontrolled proliferation, blood viscosity increases, which generates symptoms such as headaches and dizziness, visual disturbances, or erythromelalgia. As the number of all hematopoietic cells, including the granulocytes ones, increases, the difficult to control symptoms of their hyperdegranulation may appear, among which gastric ulcer or skin itching is often observed. During the disease progression, the spleen and liver become enlarged.
The most common complication of the disease is episodes of thrombosis, especially arterial one. During the course of the disease, it can also evolve into myelofibrosis or acute myeloid leukemia.
The treatment of PV is aimed at preventing thromboembolic complications, relieving the general symptoms, the appearance of hepatosplenomegaly as well as preventing its progression.
Each patient should receive an antiplatelet drug chronically, and usually acetylsalicylic acid is the choice. Most often, the treatment is started with phlebotomy in order to rapidly lower the hematocrit level. If cytoreductive therapy is necessary, the drugs of first choice are hydroxycarbamide and interferon [2].
However, the research on the mechanism of the action of interferons is still ongoing. In vitro studies with CD34+ cells from peripheral blood of patients diagnosed with polycythemia vera showed that interferon inhibits clonal changed cells selectively. It was found that interferon alpha-2b and pegylated interferon alpha-2a reduce the percentage of cells with JAK2 V617F mutation by about 40%. Pegylated interferon alpha-2a works by activating mitogen-activated protein kinase P38. It affects CD34+ cells of patients with polycythemia vera by increasing the rate of their apoptosis [6].
A case of a patient with PV with a confirmed chromosomal translocation t(6;8) treated with interferon alpha-2b, which resulted in a reduction of the clone with translocation by 50% from the baseline value, was also described [14].
In 2019, the results of a phase II multicenter study were published, which aimed at assessing the effectiveness of recombinant pegylated interferon alpha-2a in cases of refractory to previously hydroxycarbamide therapy. The study included 65 patients with essential thrombocythemia (ET) and 50 patients with polycythemia vera. All patients had previously been treated with hydroxycarbamide and showed resistance to this drug or its intolerance.
The assessment of the response was performed after 12 months of treatment. Overall response rate to interferon was higher in patients diagnosed with ET than in patients with polycythemia vera. In essential thrombocythemia, the percentage of achieved complete remissions was 43 and 26% of partial remissions. The remission rate in ET patients was higher if calreticulin CALR gene mutation was present. Patients with polycythemia vera achieved complete remission in 22% of cases and partial remission in 38% of cases.
Treatment-related side effects that follow to discontinuation of treatment were reported in almost 14% of patients [15].
The duration of response to treatment with pegylated interferon alpha-2a and the assessment of its safety in long-term use in patients with chronic myeloproliferative disorders was the goal of a phase II of the single-center study. Forty-three adult patients with polycythemia vera and 40 patients with essential thrombocythemia were enrolled in the study. The complete hematological response was defined as a decrease in hemoglobin concentration below 15.0 g/l, without phlebotomies, a resolution of splenomegaly, and no thrombotic episodes in the case of PV, and for essential thrombocythemia—a decrease platelet count below 440,000/μl and two other conditions as above. The assessment of the hematological response was performed every 3–6 months. The median follow-up was 83 months.
The hematological response was obtained in 80% of cases for the entire group. In patients with polycythemia vera, 77% of patients achieved a complete response (CR) while 7% a partial response (PR). The duration of response averaged 65 months for CR and 35 months for PR. In the group of patients diagnosed with essential thrombocythemia, CR was achieved in 73% and PR in 3%. The durance of CR was 58 months and PR was 25 months.
The molecular response for the entire group was achieved in 63% of cases.
The overall analysis showed that the duration of hematological remission and its achievement with pegylated interferon alpha-2a treatment is not affected neither by baseline disease characteristics nor JAK2 allele burden and disease molecular status. There was also no effect on age, sex, or the presence of splenomegaly.
During the course of the study, 22% of patients discontinued the treatment, because of toxicity. Toxicity was the greatest at the beginning of treatment. The starting dose was 450 μg per week and was gradually tapered off.
Thus, on the basis of the above observations, the researchers established that pegylated interferon alpha-2a may give long-term hematological and molecular remissions [16].
The assessment of pegylated interferon alpha-2a in group of patients diagnosed with polycythemia vera only was performed. The evaluation was carried out on a group of 27 patients. Interferon decreased the JAK2 V617F allele burden in 89% of cases. In three patients who were JAK2 homozygous at baseline, after the interferon alpha-2a treatment wild-type of JAK2 reappeared. The reduction of the JAK2 allele burden was estimated from 49% to an average 27%, and additional in one patient the mutant JAK2 allele was not detectable after treatment. It can therefore be postulated that the action of pegylated interferon alpha-2a is directed to cells of the polycythemia vera clone [17].
In 2005, the results of treatment by pegylated interferon alpha-2b of 21 patients diagnosed with polycythemia vera and 21 patients diagnosed with essential thrombocythemia were published. In the case of polycythemia vera in 14 patients, PRV-1 gene mutation was initially detected. In 36% of cases, PRV-1 expression normalized after treatment with pegylated interferon alpha-2b. For the entire group of 42 patients, the remission assessment showed that complete remission was achieved in 69% cases after 6 months of treatment. However, only in 19 patients remission was still maintained 2 years after the start of the study. Pegylated interferon alpha-2b was equally effective in patients with PV and ET. The use and the type of prior therapy did not affect the achievement of remission [18].
Another study with enrolled only PV patients included 136 patients. They were divided into two arms. One group received interferon alpha-2b and the other group received hydroxycarbamide. Interferon dosage was administered in 3 million units three times a week for 2 years and then 5 million units two times a week. Hydroxycarbamide was administered at a dose between 15 and 20 mg/kg/day.
In the group of patients treated with interferon, a significantly lower percentage of patients developed erythromelalgia (9.4%) and distal parasthesia (14%) compared with the group treated with hydroxycarbamide, for whom these percentages were respectively: 29 and 37.5%. Interferon alpha-2b was found to be more effective in inducing a molecular response, which was achieved in 54.7% of cases, in comparison with hydroxycarbamide—19.4% of cases, despite the fact that the percentage of achieved general hematological responses did not differ between the groups and amounted about 70%. The 5-year progression free period in the interferon group was achieved in a higher percentage (66%) than in the hydroxycarbamide group (46.7%) [19].
The most recent form of interferon approved by the
Thanks to these changes to the structure of the molecule, it was possible to achieve a significant increase in its half-life. Ropeginterferon can be administered subcutaneously to patients every 14 days. The clinical trials conducted so far have assessed the ropeginterferon dose from 50 micrograms to a maximum dose of 500 microgams administered as standard every 2 weeks. The possible dose change in case of side effects includes not only the reduction of the drug dose itself, but also the extension of the interval between doses. The extension of the dosing interval up to 4 weeks was assessed.
Ropeginterforn was approved in 2019 by the EMA for the use in patients diagnosed with polycythemia vera without splenomegaly, as monotherapy.
Ropeginterferon, like the previous forms of interferons used in treatment, is contraindicated in patients with severe mental disorders, such as severe depression. It is also a contraindication in patients with noncompensatory standard treatment of disorders of the thyroid gland as well as severe forms of autoimmune diseases. The safety profile of ropeginterferon is similar to that of other forms of alpha interferons. The most common side effects are flu-like symptoms [20].
Ropeginterferon has been shown to exhibit in vitro activity against JAK2-mutant cells. The activity of ropeginterferon against JAK2-positive cells is similar to that of other forms of interferons used actually for standard therapy. Ropeginterferon has an inhibitory effect on erythroid progenitor cells with a mutant JAK2 gene. At the same time, it has almost no effect on progenitor cells without the mutated allele (JAK2-wile-type) and normal CD34+ cells. A gradual decrease of JAK2-positive cells was observed in patients with PV during ropeginterferon treatment. The examination was performed after 6 and 12 months of treatment. In comparison, the reduction in the percentage of JAK2 positive cells in patients treated with hydroxycarbamide was significantly lower.
These results may suggest that ropeginterferon may cause elimination of the mutant clone, but further prospective clinical trials are needed to confirm this theory. The evaluation was performed on a group of patients enrolled in the PROUD-PV study who were treated in France [21].
In 2017, a multicenter study was opened in Italy. The study was of the second phase. In total, 127 patients with polycythemia vera were included in the study. All patients enrolled on the study had low-risk PV. The clinical trial consisted of two arms. Patients received phlebotomies and low-dose aspirin in one arm and ropeginterferon in the other arm. The aim of the study was to achieve a hematocrit of 45% or lower without any evidence of disease progression. Ropeginterferon was administered every 2 weeks at a constant dose of 100 μg.
The response to the treatment was assessed after 12 months. The reduction of hematocrit to the assumed level was achieved in significantly higher percentage of patients in the ropeginterferon group than of patients who received only phlebotomies and aspirin. In addition, none of the patients treated with ropeginterferon experienced disease progression during the course of the study, while among those treated with phlebotomies, 8% of patients progressed.
Grade 4 or 5 adverse events were not observed in patients treated with ropeginterferon, and the incidence of remaining adverse event (AE) was small and comparable in both arms. The most common side effects in the ropeginterferon group were flu-like symptoms and neutropenia; however, the third-grade neutropenia was the most common (8% of cases) [22].
One of the most important clinical studies on the use of ropeginterferon was the PROUD-PV study and its continuation: the CONTINUATION-PV study. These were three-phase, multicenter studies. The aim of the study was to compare the effectiveness of ropeginterferon in relation to hydroxycarbamide. The study included adult patients diagnosed with polycythemia vera treated with hydroxycarbamide for less than 3 years and no cytoreductive treatment at all. In total, 257 patients received this treatment. The patients were divided into two groups: those receiving ropeginterferon or the other being given hydroxycarbamide.
During the PROUD-study, drug doses were increased until the hematocrit was achieved below 45% without the use of phlebotomies, and the normalization of the number of leukocytes and platelets was reached.
The PROUD-PV study lasted 12 months. After this time, the patients continued the treatment under the CONTINUATION-PV study for further 36 months. After the final analysis performed in the 12th month at the end of PROUD study, it was found that the hematological response rates did not differ between the ropeginterferon and hydroxycarbamide treatment groups. These were consecutively 43% in the ropeginterferon arm and 46% in the control arm.
However, after analyzing the CONTINUATION- PV study, it turned out that after 36 months of treatment, the rates of hematological responses begin to prevail in the group of patients receiving ropeginterferon, 53% versus 38% in the control group. Thus, from the above data, it can be seen that the response rate to ropeginterferon increases with the duration of treatment [23].
Another analysis of patients participating in the PROUD and CONTINUATION studies was based on the assessment of treatment results after 24 months, dividing patients into two groups according to age (under and over 60 years).
The initial comparison of both groups of patients showed that older patients had a more aggressive course of the disease. Patients over 60 years of age had a higher percentage of cells with a mutant JAK2 allele. They experienced both general symptoms and some complications, such as thrombosis, more frequently. Both patients under 60 years of age and over 60 years of age in the ropeginterferon arm had a higher rate of molecular response, namely 77.1 and 58.7% compared with the HU remission: 33.3 and 36.1%, respectively. Significantly higher reductions in the JAK2 allele were observed in both groups of patients after ropeginterferon treatment: it was 54.8% for younger patients and 35.1% for elderly patients. For comparison, this difference in the group of patients treated with HU was 4.5 and 18.4%, respectively.
What is more, the age did not affect the frequency of ropeginterferon side effects. In addition, the incidence of adverse ropeginterferon disorders was similar to that observed in the hydroxycarbamide group [24].
Essential thrombocythemia is a clonal growth of multipotential stem cells in the bone marrow. The consequence of this is increased proliferation of megakaryocytes in the bone marrow and an increase in the number of platelets in the peripheral blood. The level of platelets above 450,000/μl is considered a diagnostic criterion.
Essential thrombocythemia may progress over time to a more aggressive form of myeloproliferation, i.e., myelofibrosis. The disease can also evolve into acute myeloid leukemia or myelodysplastic syndrome, both with very poor prognosis. Thromboembolic complications are serious, and they concern over 20% of patients. Thrombosis occurs in the artery and venous area. Moreover, in patients with a very high platelet count, above 1,000,000/μl, bleeding may occur as a result of secondary von Willebrand syndrome [1, 2].
The treatment of ET is primarily aimed to prevent thrombotic complications.
In low-risk patients, only acetylsalicylic acid is used. In cases of high-risk patients, hydroxycarbamide is the first-line drug for most patients. Anagrelide and interferon are commonly used as second-line drugs.
Due to the possible effects of hydroxycarbamide of cytogenetic changes in the bone marrow cells after long-lasting usage, some experts recommend the use of interferon in younger patients in the first line. Interferon is also used as the drug of choice in patients planning a pregnancy [25].
The efficacy of pegylated interferon alpha-2a was assessed on the basis of the group of 39 patients with essential thrombocythemia and 40 patients with polycythemia vera.
Of the overall group, 81% of patients were previously treated prior to the study entry. The patients received pegylated interferon alpha-2a in a dose of 90 μg once a week. The dose of 450 μg was associated with a high percentage of intolerance.
In patients with essential thrombocythemia, the complete remission was achieved in 76%, while the overall hematological response rate brought 81%. Moreover, the molecular remission was achieved in 38%, in 14% of cases, JAK2 transcript became not detectable.
Patients diagnosed with polycythemia vera achieved 70% complete hematological remission and 80% general hematological response to treatment. JAK2 transcript was undetectable in 6% of patients. Molecular remission was achieved in 54% of cases.
Pegylated interferon alpha-2a at the dose of 90 μg per week was very well tolerated. In total, 20% of patients experienced a grade of 3 or 4 of adverse reaction, which was neutropenia. In addition, an increase in liver function tests was observed. Grade 4 of AE was not observed among patients who started the treatment with 90 μg/week while grade 3 neutropenia was an adverse event in only 7% of cases [26].
The effect of interferon alpha-2b treatment in patients with ET and PV was investigated. The study was prospective. Some of the results concerning the group of patients with polycythemia vera are presented in the subsection on polycythemia vera. In total, 123 patients with diagnosed essential thrombocythemia participated in the study. All of them received interferon alpha-2b. The patients were divided into two groups depending on the presence of the JAK2 V617F mutation. The enrolled patients were between 18 and 65 years of age. The treatment they received was, sequentially, interferon alpha-2b in the dose of 3 million units three times a week for the first 2 years, after which time the dose was changed into a maintenance dose, which amounted to 5 million units two times a week.
The analysis showed that the patients with the JAK2 V617F mutation present in a higher percentage achieved an overall hematological response as well as a complete hematological response. The overall hematological response was achieved in 83% of patients with JAK2 mutation, and the complete hematological remission was achieved in 23 cases. In the group of ET patients without the JAK2 V617F mutation, overall hematological response was achieved in 61.4%, while the complete hematological remission was achieved in 12 patients. The 5-year progression-free survival was obtained in 75.9% in the JAKV617F group and only in 47.6% without the mutation.
A significant proportion of patients experienced mild side effects. Grade 3 and 4 of adverse events were severe, most of them being a fever. The isolated cases of elevated liver tests and nausea have also been reported [19].
Pegylated interferon alpha-2b in patients with essential thrombocythemia who were previously treated with hydroxycarbamide, anagrelide, and other forms of interferon alpha, however, due to the lack of efficacy or toxicity, the patients required a change of treatment, was assessed. Pegylated interferon alpha-2b turned out to be effective in these cases. It led to the complete hematological remission in 91% of patients after 2 months of therapy, and in 100% of patients after 4 months. However, merely 11 patients participated in the study. Also only two patients required treatment discontinuation due to the side effects such as depression and general fatigue grade 3 [27].
In case of pregnant patients, interferon is currently considered the only safe cytoreductive drug. Over the years, several analyses of the results of interferon treatment during pregnancy have been carried out.
The assessment of 34 pregnancies in 23 women diagnosed with ET was performed retrospectively. All the pregnancies included in the analysis were of high risk. This high risk was associated with a high platelet count above 1,500,000/μl, a history of thrombotic episode, severe microcirculation disorders, or a history of major hemorrhage.
It turned out that the use of interferon allowed the birth of an alive child in 73.5% of cases. There was no difference in efficacy between the basic and pegylated forms of interferon alpha. In pregnancies without interferon treatment, the percentage of live births was only 60%. Moreover, it was not found if the presence of the JAK2 V617F mutation had any influence on the course of pregnancy [28].
An analysis of the course of pregnancy in patients with ET was assessed in Italy. Data from 17 centers were taken into account. Data from 122 pregnancies were collected from 92 women. In patients diagnosed with essential thrombocythemia, the risk of the spontaneous loss of pregnancy is about 2.5 times higher than among the general population. In the contrary to the study quoted above, it was found that the presence of the JAK2 mutation increases the risk of pregnancy loss. The proportion of live births in patients exposed to interferon during pregnancy was 95%, compared with 71.6% in the group of patients not treated with interferon.
The multivariate analysis also showed that the use of acetylsalicylic acid during pregnancy had no effect on the live birth rate of patients with ET [29].
Whatever its form, interferon is the drug of first choice in pregnancy. Hydroxycarbamide and anagrelide should be withdrawn for about 6 months, and at least for 3 months, before the planned conception. Experts recommend the use of interferon in high-risk pregnancies [30]. A Japanese analysis of 10 consecutive pregnancies in ET patients showed 100% live births in patients who received interferon [31].
In myelofibrosis (MF), monoclonal megakaryocytes produce cytokines that stimulate the proliferation of normal, non-neoplastic fibroblasts and stimulate angiogenesis. The consequence of this is the gradual fibrosis of the bone marrow, impaired hematopoiesis in the bone marrow, and the formation of extramedullary location mainly in the sites of fetal hematopoiesis, i.e., in the spleen and the liver.
The production of various cytokines by neoplastic megakaryocytes leads to the proliferation of normal, noncancerous fibroblasts as well as to increased angiogenesis.
Progressive bone marrow fibrosis leads to worsening anemia and thrombocytopenia. On the other hand, the production of proinflammatory cytokines by megakaryoblasts leads to the general symptoms such as weight loss, fever, joint pain, night sweats, and consequently, progressive worsening of general condition.
The prognosis for myelofibrosis is poor. In about 20% of patients, myelofibrosis evolves into acute myeloid leukemia with poor prognosis.
Currently, the only effective method of treatment that gives a chance to prolong the life is allogeneic bone marrow transplantation. However, this method is only available to younger patients.
The goal of treatment of patients who have not been qualified for allotranspalntation is to reduce the symptoms and to improve the patient’s quality of life. In case of leukocytosis cytoreducing drugs, such as hydroxycarbamide, melphalan, or cladribine can be used. They cause a reduction in the number of leukocytes and may, to some extent, inhibit splenomegaly. Interferon alpha has been used successfully for the treatment of myelofibrosis for many years. The results of its effectiveness will be presented below [2].
Currently, the JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis with enlarged spleen in intermediate and high-risk patients. Ruxolitinib reduces the size of the spleen, reduces general symptoms, and improves the quality of life; however, it does not prolong the overall survival of patients [32].
In 2015, the results of a retrospective study were published to compare the histological parameters of the bone marrow before and after interferon treatment. Twelve patients diagnosed with primary myelofibrosis as well as post-PV MF and post-ET MF were enrolled in the study. Patients were treated with pegylated recombinant interferon alpha-2a or recombinant interferon alpha-2b in standard doses. The time of treatment was from 1 to 10 years. Some patients had previously been treated with hydroxycarbamide or anagrelide. In all cases, karyotype was normal. The prognostic factor of Dynamic International Prognostic Scoring System (DIPSS) was assessed at the beginning as well as during the treatment.
Bone marrow cellularity decreased in cases with increased bone marrow cellularity before the treatment. After the interferon treatment, a reduction in the degree of bone marrow fibrosis was found. The parameters, such as the density of naked nuclei and the density of megakaryocytes in the bone marrow, also improved.
It proves that if the JAK2 V617F mutation had been present, DIPSS was decreased after interferon treatment. This relationship was not observed in patients without the JAK2 V617F mutation. The improvement in peripheral blood morphological parameters and the overall clinical improvement correlated with the improvement in the assessed histological parameters of the bone marrow.
Before the initiation of interferon, seven patients had splenomegaly. During the treatment with interferon, the complete resolution of splenomegaly was achieved in 17% of patients (two cases), and its size decreased in 25% (three cases). A good clinical response was achieved in 83% during interferon therapy. There was no significant difference in response between the two types of interferon used [33].
A prospective study was also conducted in patients with low and intermediate-1 risk group myelofibrosis. Seventeen patients were enrolled. Patients received interferon alpha-2b (0.5–3 milion units/three times a week) or pegylated interferon alpha-2a (45–90 μg/week). The duration of therapy was on average 3.3 years.
Most of the patients responded to the treatment. Partial remission was found in seven patients and complete remission in two patients. Moreover, in four cases, the disease was stabilized and in one case the clinical improvement was achieved. Three patients did not respond to treatment at all and progressed to myelofibrosis. Additionally, the assessment in reducing spleen size was performed. At baseline, 15 patients have splenomegaly, nine of them achieved the compete regression of spleen size [34].
However, the efficacy of interferon in the treatment of myelofibrosis appears to be limited only to a less advanced form, when the bone marrow still has an adequate percentage of normal hemopoiesis and the marrow stroma is not significantly fibrotic. In more advanced stages, interferon was not shown to have any significant effect on the regression of the fibrosis process [35].
In 2020, the results of the COMBI study were published. That was a two-phase, multicenter, single-arm study that investigated the efficacy and safety of the combination of ruxolitinib and pegylated interferon alpha. Thirty-two patients with PV and 18 patients with primary and secondary myelofibrosis participated in the study. The patients were at age 18 and older. Remission was achieved in 44% of myelofibrosis cases, including 28% (5 patients) of complete remission. In patients with PV, the results were slightly worse: 31% of remissions, including 9% of complete remissions. Patients received pegylated interferon alpha-2a (45 μg/week) or pegylated interferon alpha-2b (35 μg/week) in low doses and ruxolitinib in doses of 5–20 mg twice a day.
For the entire group of patients (with PV and MF), the initial JAK2 allele burden was 47% at baseline, and after 2 years of treatment with interferon and ruxolitinib, it decreased to 12%.
The treatment toxicity was low. The highest incidence of side effects occurred at initiation of therapy. It was mostly anemia and thrombocytopenia.
The observations from the COMBI study show that, for the combination of interferon in lower doses with ruxolitinib, it may be effective and well tolerated even in the group of patients who had intolerance to interferon used as the only drug in higher doses. The combined treatment improved the bone marrow in terms of fibrosis and its cellularity. It also allowed to improve the value of peripheral blood counts [36].
It is currently known that some of the additional mutations are associated with a worse prognosis in patients with myelorpoliferation, including patients with myelofibrosis. Some of these mutations have been identified as high-risk molecular mutations. These are ASXL1, EZH2, IDH1/2, or SRSF2. Earlier studies have shown their association with a more aggressive course of the disease, worse prognosis, and shorter survival of patients, as well as a poorer response to treatment. Due to their importance, they have been included in the diagnostic criteria of myelofibrosis [37].
It is also known that the presence of driver mutations, i.e., JAK2, CALR, and MPL or triple negativity, may affect the course of myeloproliferation, including the incidence of thromboembolic complications.
The assessment of the influence of driver mutations and a panel of selected additional mutations on the effectiveness of interferon treatment in patients with myelofibrosis was performed on a group of 30 patients. Only the patients with low- and intermediate-1-risk were enrolled in the study. The treatment with pegylated interferon alpha-2a or interferon alpha-2b resulted in a complete remission in two patients and partial remission in nine patients. The disease progressed in three cases. One patient relapsed and four died. The remaining patients achieved a clinical improvement or disease stabilization. In the studied group, it was not found if the effectiveness of interferon treatment was influenced by the lack of driver mutations. Among the group of four patients with additional mutations, two died and one had disease progression. It was a mutation of ASXL1 and SRSF2. The treatment with interferon in patients without additional molecular mutations in the early stages of the disease may prevent further progression of the disease [38].
The side effects of interferon in the group of patients with myelofibrosis are similar to those occurring after the treatment of other chronic myeloproliferative diseases. The most frequently described are hematological toxicity- anemia and thrombocytopenia, less often is the appearance of leukopenia. Hematological toxicity usually resolves with dose reduction or extension of the dose interval. The most frequently nonhematological toxicity was fatigue, muscle pain, weakness, and depression symptoms. All symptoms are usually mild and do not exceed grade 2 [38].
However, the use of interferon in the treatment of myelofibrosis has not been recommended as a standard therapy. Interferon is still being evaluated in clinical trials, or it is used in selected patients as a nonstandard therapy in this diagnosis.
Mastocytosis is characterized by an excessive proliferation of abnormal mast cells and their accumulation in various organs.
The basis for the development of mastocytosis is ligand-independent activation of the KIT receptor, resulting from mutations in the KIT proto-oncogene. The KIT receptor is a trans membrane receptor with tyrosine kinase’s activity. Its activation stimulates the proliferation of mast cells. That excessive numbers of mast cells infiltrate tissues and organs and release mediators such as histamine, interleukine-6, tryptase, heparin, and others, which are responsible for the appearance of symptoms typical of mastocytosis. In addition, the infiltration of tissues for mast cells itself causes damage to the affected organs.
The prognosis of mastocytosis depends on the type of the disease. In the case of cutaneous mastocytosis (CM), in the majority of cases prognosis is good and the disease does not shorten the patient’s life, but in aggressive systemic mastocytosis (ASM), the average follow-up is about 40 months. Mast cell leukemia has a poor prognosis with a median follow-up of approximately 1 year.
Systemic mastocytosis usually requires the implementation of cytoreductive therapy. The first line of therapy is interferon alone or its combination with corticosteroids. In aggressive systemic mastocytosis, the first line in addition to interferon 2-CdA can be used. An effective drug turned out to be midostaurin in the case of the present KIT mutation. In patients without the KIT D816V mutation, treatment with imatinib may be effective. In the case of mast cell leukemia, multidrug chemotherapy is most often required, as in acute leukemias, followed by bone marrow transplantation [39].
Systemic mastocytosis requiring treatment is a rare disease, this is why the studies available in the literature evaluating various therapies concern mostly small groups of patients.
In 2002, the French authors presented their experiences on the use of interferon in patients with systemic mastocytosis. They included 20 patients. The patients received interferon alpha-2b in gradually increased doses.
The patients were assessed after 6 months. In cases in which bone marrow was infiltrated for mast cells at baseline, it still remained infiltrated after 6 months of treatment.
However, the responses were obtained in terms of symptoms related to mast cell degranulation. Partial remission was achieved in 35% of patients and minor remission in 30%. It concerns mainly skin lesions and vascular congestion. Moreover, the assessment of the histamine level in the plasma revealed a decrease of it in patients who previously presented symptoms related to the degranulation of mast cells, such as gastrointestinal disorders and flushing.
A high percentage of side effects were found during treatment. They concerned 35% of patients. Depression and cytopenia were most frequent ones [40].
Another analysis was a report of five patients with systemic mastocytosis treated with interferon and prednisolone. All patients received interferon alpha-2b in a dose of 3 million units three times a week and four patients additionally received prednisolone. Four patients responded to interferon treatment at varying degrees. One patient, who at baseline had bone marrow involvement by mast cells in above 10%, progressed to mast cell leukemia. In two patients, the symptoms C resolved completely and in one of them they partially disappeared. In one case, stabilizing disease was achieved [41].
In 2009, a retrospective analysis of patients treated with cytoreductive therapy due to mastocytosis was published. The authors collected data from 108 patients treated at the Mayo Clinic. This analysis allowed for the comparison of the efficacy of four drugs used in systemic mastocytosis. There were interferon alpha alone or in the combination with prednisone—among 40 patients, hydroxycarbamide—among 26 ones, imatinib—among 22 persons, and 2-chlorodeoxyadenosine (2-CdA)—among 22 patients.
After dividing the patients into three additional groups on the basis of the type of mastocytosis—indolent systemic mastocytosis, aggressive systemic mastocytosis, and systemic mastocytosis associated with another clonal hematological nonmast cell lineage disease (SM-AHNMD)—the effectiveness of each of type of therapy was assessed.
The highest response rates in indolent and aggressive mastocytosis were achieved with interferon treatment. They were 60% of the responses in both groups, and in the SM-AHNMD group of patients, the percentage was also one of the highest and amounted to 45%. The second most effective drug was 2-CdA. The response rates were 56% for indolent MS, 50% for aggressive MS, and 55% for SM-AHNMD. The patients treated with imatinib achieved response in 14, 50, and 9% by following groups, respectively. In contrast, patients with indolent and aggressive systemic mastocytosis did not respond to hydroxycarbamide treatment at all. The response rate in both groups was 0%. However, patients with MS associated with another clonal hematological nonmast cell lineage disease achieved 21% response to hydroxycarbamide. Additionally, it was found that only interferon relieved symptoms caused by the release of inflammatory mediators by mast cells.
The additional analysis showed no influence of the TET 2 mutation on the response to treatment [42].
In the literature, there are also single cases of mastocytosis presenting trials of nonstandard treatment. That is description of a patient with systemic mastocytosis with mast cell bone marrow involvement. Mutation of c-kit Asp816Val was present. Patient progressed despite treatment with dasatinib and 2-chlorodeoxyadenosine. The patient developed symptoms related to the degranulation of mast cells and increased ascites.
The patient was treated with pranlukast, which is an anti-leukotriene receptor antagonist due to an asthma episode. The rate of ascites growth decreased significantly after one administration. The patient required paracentesis every 10 days and not every 3 days, as before starting to take the drug. After 15 days of treatment with pranlukast, the patient received interferon alpha, which resulted in complete regression of ascites, resolution of pancytopenia, and complete disappearance of the c-kit mutation clone. The infiltration of mast cells in the bone marrow significantly decreased [43].
Interferon alpha was also effective in a patient with systemic mastocytosis associated with myelodysplastic syndrome with the c-kit D816V mutation, which was refractory to imatinib treatment [44].
Interferon alpha also proved to be effective in the treatment of osteoporotic lesions appearing in the course of mastocytosis.
The series of 10 cases with resolved mastocytosis and osteoporosis-related fractures was presented in 2011. The patients received interferon alpha in a dose of 1.5 million units three times a week as well as pamindronic acid. The patients were treated for an average of 60 months. For the first 2 years, pamindronate was given at a dose of 1 mg/kg every month, and then every 3 months.
During the course of the study, no patient had a new-bone fracture. The level of alkaline phosphatase decreased by 25% in relation to the value before treatment and tryptase by 34%. Bone density increased during treated with interferon and pamindronate. The increase was on average 12% in the spine bones and 1.9% in the hip bones. At the same time, there was no increase in the density of the hip bone and a minimal increase in the density of the spine in patients treated with pamindronate alone.
The results of this observation suggest that it is beneficial to add low doses of interferon alpha to pamindronate treatment in terms of bone density increase [45].
That experiences show that interferon used in systemic mastocytosis significantly improves the quality of life of patients by inhibiting the symptoms caused by degranulation of mast cells. They prevent bone fractures and, in some patients, they cause remission of bone marrow infiltration by mast cells.
Chronic neutrophilic leukemia (CNL) is a very rare disease. It is characterized by the clonal proliferation of mature neutrophils.
The diagnostic criteria proposed by the World Health Organization (WHO) comprise leukocyte counts above 25,000/μl (including more than 80% of rod and segmented
Physical examination often shows enlargement of the liver and spleen, moreover, patients complain on weight loss and weakness [1].
The prognosis varies. The average survival time for patients with CNL is less than 2 years.
Only few descriptions of chronic neutrophilic leukemia are available in the literature, and these are mostly single case reports.
Because it is an extremely rare disease, there are no established and generally accepted treatment standards. In most cases, patients are given hydroxycarbamide or interferon. Patients who are eligible for a bone marrow transplant may benefit from this treatment. Bone marrow allotransplantation remains the only method that gives a chance for a significant extension of life.
The German authors presented a series of 14 cases of chronic neutrophilic leukemia. The group of patients consisted of eight women and six men. The average age was 64.7 years. From the entire group of patients, longer survival was achieved only in three cases. One of these patients was treated with interferon alpha and achieved hematological remission, the other underwent bone marrow allotransplantation from a family donor, and the third one was treated with hydroxycarbamide and transfusions as needed. The follow-up period of the patient after allogeneic matched related donor transplantation (allo-MRD) was 73 months, and for the patient after interferon treatment it was 41 months.
The remaining patients died within 2 years of diagnosis. Six patients, the largest group, died due to intracranial bleeding, three patients died because of leukemia cell tissue infiltration, one patient because of the disease transformation into leukemia, and one patient because of pneumonia [46].
It can be seen from these experiences that treatment with interferon alpha can significantly extend the survival time of patients.
The case of a 40-year-old woman diagnosed with chronic neutrophilic leukemia is presented by Yassin and coauthors. Initially, the patient had almost 41,000 leukocytes in the peripheral blood. In a physical examination, splenomegaly and hepatomegaly were not present. Patient received pegylated interferon alpha-2a. The initially dose was 50 μg once a week for the first 2 weeks, then the dose was increased to 135 μg weekly for 6 weeks, and then the dose interval was extended to another 2 weeks. As a result of the treatment, the general condition of the patient improved and the parameters of peripheral blood counts were normalized [47].
Another case report presented in the literature describes a 41-year-old woman diagnosed with CNL accompanied by focal segmental glomerulosclerosis (FSGS). The patient had increasing leukocytosis for several months. On the admission to the hospital, leukocytosis was 94,000/μl. Moreover, the number of platelets in the morphology exceeded 1,000,000/μl. More than a year earlier, the patient had splenectomy due to splenomegaly and spleen infraction.
Additionally, JAK2 V617F mutation was found. Some authors suggest that the presence of JAK2 mutation may be associated with longer survival in CNL.
The patient received hydroxycarbamide for 3 months and reduction in the number of leukocytes was achieved. After this time, interferon alpha-2b was added to hydroxycarbamide. As a result, focal segmental glomerulosclerosis disappeared and the renal tests improved [48].
Another case of chronic neutrophilic leukemia with a JAK2 gene mutation concerns a 53-year-old man. The patient’s baseline leukocytosis was 33,500/μl, including the neutrophil count of 29,700/μl. The patient also had splenomegaly.
The treatment with interferon alpha-2b at a dose of 3 million units every other day was started. After a month of treatment, the number of leukocytes was reduced to less than 10,000/μl. Then the patient was treated chronically with interferon alpha-2b in doses of 3 million units every 2 weeks. As a result of the therapy, the number of leukocytes remains between 8 and 10,000/μl. The patient remains in general good condition [49].
A series of two CNL cases are also shown. The first patient was a 70-year-old woman with stable leukocytosis of about 35,000/μl and the remaining morphology parameters in normal range. The patient was only observed for 5 years until hepasplenomegaly progressed rapidly. Then, interferon alpha-2b was included. Due to the treatment, the rapid regression of hepatosplenomegaly was achieved.
The second case is a 68-year-old woman with baseline leukocytosis of almost 14,000/μl. In this case, the treatment with hydroxycarbamide was started immediately. However, no improvement was achieved. After 6 weeks of HU treatment, interferon alpha-2b 3 million units 3 times a week was implemented and leukocytosis decreased. Due to the interferon treatment, the disease stabilized for a long time. Because the patient experienced an adverse reaction, a severe flu-like syndrome, interferon was discontinued. After interferon withdrawal, the disease progressed gradually and the treatment attempts by busulfan and 6-mercaptopurine were unsuccessful. Therefore, interferon was readministered and the disease went into remission. Interferon treatment was continued at a reduced dose. The disease regression was achieved again.
Additionally, the patient showed an improvement in the function of granulocytes in terms of phagocytosis and an improvement in neutral killer (NK) cell function after treatment with interferon [50].
The above examples show that interferon alpha is effective in the treatment of chronic neutrophilic leukemia. The side effects are rare and can be managed with dose reductions. Moreover, in these cases, interferon is also effective in a reduced dose. Disease remission or regression can be achieved without typical of CNL complications, such as intracranial bleeding.
Interferon has been used in the past to treat chronic myeloid leukemia. The treatment with tyrosine kinase inhibitors is now a standard practice. However, in a small number of patients, they are ineffective or exhibit unmanageable toxicity. Therefore, the attempts are underway to use interferon in combination with TKI in lower doses, which is to ensure the enhancement of the antiproliferative effect while reducing the toxicity.
There are ongoing attempts to use ropeginterferon in patients diagnosed with chronic myeloid leukemia, in whom treatment with imatinib alone has not led to deep molecular response (DMR). The first phase study was conducted in a small group of patients with chronic myeloid leukemia. The patients in first chronic phase treated with imatinib who did not achieve DMR, but in complete hematologic remission and complete cytogenetic remission, were included in the study. Patients have been treated with imatinib for at least 18 months. Twelve patients were enrolled in the study, and they completed the study according to the protocol. These patients received additional ropeginterferon to imatinib and four achieved DMR. Low toxicity was observed during the treatment. Among the hematological toxicities, neutropenia was the most common. There was no nonhematological toxicity with a degree higher than 1/2 during the treatment. Moreover, it has been found that better effects and fewer side effects are obtained when ropeginterferon is administered for a longer time, but in lower doses. The comparison of the effectiveness of interferon in chronic myeloproliferative disorders based on selected articles is presented in Table 1 [51].
Source | Type of trial | Interferon | Diagnosis | No. | Prior treatment status | Response rate |
---|---|---|---|---|---|---|
Yacoubet al. [15] | Phase II, multicenter | Pegylated IFN alfa-2a | PV | 50 | Resistance to HU or HU intolerance | CR:22% PR:38% |
ET | 65 | CR:43% PR:26% | ||||
Masarova et al. [16] | Phase II, single-center | Pegylated IFN alfa-2a | PV | 43 | Untreated or previously treated with cytoreductive therapy | CR:77% PR:7% |
ET | 40 | CR:73% PR:3% | ||||
Samuelsson et al. [18] | Phase II | Pegylated IFN alfa-2b | PV | 21 | Untreated or previously treated with cytoreductive therapy | CR: 69% for the entire group |
ET | 21 | |||||
Huang BT et al. [19] | Open label, multicenter | IFN alfa-2b | PV | 136 | Untreated or previously treated with cytoreductive therapy | OHR:70% Molecular response:54.7% |
ET | 123 | OHR (JAK2+ patients):83% CHR:23 cases OHR (JAK2-patients): 61.4% CHR:12 cases | ||||
Gisslinger et al. [23] | phase III, multicenter | Ropeginterferon | PV | 257 | Previously treated | OHR:53% |
Quintás-Cardama et al. [26] | phase II | Pegylated IFN alfa-2a | PV | 40 | Untreated or previously treated with cytoreductive therapy | OHR:80% CR:70% Molecular remission:54% |
ET | 39 | OHR:81% CR:76% Molecular remission:38% | ||||
Sørensen et al. [36] | Phase III, multicenter, COMBI | Pegylated IFN alfa-2a with ruxolitinib or Pegylated IFN alfa-2b with ruxolitinib | PV | 32 | Untreated or previously treated with cytoreductive therapy | OHR:44% CR:28% |
MF | 18 | OHR:31% CR:9% | ||||
Casassus et al. [40] | Open label, multicenter | IFN alpha-2b | Mastocytosis | 20 | Untreated and previously treated | PR:35% Minor remission: 30% |
Comparison of the effectiveness of interferon in chronic myeloproliferative disorders.
PV: polycythemia vera; ET: essential thrombocythemia; MF: myelofibrosis; HU: hydroxycarbamide/hydroxyurea; CR: complete remission; PR: partial remission; and OHR: overall hematological response.
Interferon alpha appears to be an effective and safe drug in the most type of chronic myeloproliferative disorders. Nowadays, all forms of its using have similar effectiveness. Interferon alpha can be effective even in cases of resistance for first-line treatment. Trial research is currently underway to combine it with some new drugs, such as ruxolitinib, and to add it to the already well-established therapy, it is a promising option for patients with refractory disease.
From time to time, new forms of interferon, such as ropeginterferon, are introduced, which gives hope for better effectiveness, better safety profile, and greater comfort in its use for patients who have to be treated for many years. In the case of the use of interferons alpha in the treatment of chronic myeloproliferative diseases, there are still opportunities to extend its use and to study its combination with newly introduced drugs.
The Open Access model is applied to all of our publications and is designed to eliminate subscriptions and pay-per-view fees. This approach ensures free, immediate access to full text versions of your research.
",metaTitle:"Open Access Publishing Fees",metaDescription:"Open Access Publishing Fees",metaKeywords:null,canonicalURL:"/page/OA-publishing-fees",contentRaw:'[{"type":"htmlEditorComponent","content":"As a gold Open Access publisher, an Open Access Publishing Fee is payable on acceptance following peer review of the manuscript. In return, we provide high quality publishing services and exclusive benefits for all contributors. IntechOpen is the trusted publishing partner of over 140,000 international scientists and researchers.
\\n\\nThe Open Access Publishing Fee (OAPF) is payable only after your book chapter, monograph or journal article is accepted for publication.
\\n\\nOAPF Publishing Options
\\n\\nDuring the launching phase journals do not charge an APC, rather they will be funded by IntechOpen.
\\n\\n*These prices do not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT as long as provision of the VAT registration number is made during the application process. This is made possible by the EU reverse charge method.
\\n\\nServices included are:
\\n\\nWhat isn't covered by the Open Access Publishing Fee?
\\n\\nIf your manuscript:
\\n\\nYour Author Service Manager will inform you of any items not covered by the OAPF and provide exact information regarding those additional costs before proceeding.
\\n\\nOpen Access Funding
\\n\\nTo explore funding opportunities and learn more about how you can finance your IntechOpen publication, go to our Open Access Funding page. IntechOpen offers expert assistance to all of its Authors. We can support you in approaching funding bodies and institutions in relation to publishing fees by providing information about compliance with the Open Access policies of your funder or institution. We can also assist with communicating the benefits of Open Access in order to support and strengthen your funding request and provide personal guidance through your application process. You can contact us at funders@intechopen.com for further details or assistance.
\\n\\nFor Authors who are still unable to obtain funding from their institutions or research funding bodies for individual projects, IntechOpen does offer the possibility of applying for a Waiver to offset some or all processing feed. Details regarding our Waiver Policy can be found here.
\\n\\nAdded Value of Publishing with IntechOpen
\\n\\nChoosing to publish with IntechOpen ensures the following benefits:
\\n\\nBenefits of Publishing with IntechOpen
\\n\\nAs a gold Open Access publisher, an Open Access Publishing Fee is payable on acceptance following peer review of the manuscript. In return, we provide high quality publishing services and exclusive benefits for all contributors. IntechOpen is the trusted publishing partner of over 140,000 international scientists and researchers.
\n\nThe Open Access Publishing Fee (OAPF) is payable only after your book chapter, monograph or journal article is accepted for publication.
\n\nOAPF Publishing Options
\n\nDuring the launching phase journals do not charge an APC, rather they will be funded by IntechOpen.
\n\n*These prices do not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT as long as provision of the VAT registration number is made during the application process. This is made possible by the EU reverse charge method.
\n\nServices included are:
\n\nWhat isn't covered by the Open Access Publishing Fee?
\n\nIf your manuscript:
\n\nYour Author Service Manager will inform you of any items not covered by the OAPF and provide exact information regarding those additional costs before proceeding.
\n\nOpen Access Funding
\n\nTo explore funding opportunities and learn more about how you can finance your IntechOpen publication, go to our Open Access Funding page. IntechOpen offers expert assistance to all of its Authors. We can support you in approaching funding bodies and institutions in relation to publishing fees by providing information about compliance with the Open Access policies of your funder or institution. We can also assist with communicating the benefits of Open Access in order to support and strengthen your funding request and provide personal guidance through your application process. You can contact us at funders@intechopen.com for further details or assistance.
\n\nFor Authors who are still unable to obtain funding from their institutions or research funding bodies for individual projects, IntechOpen does offer the possibility of applying for a Waiver to offset some or all processing feed. Details regarding our Waiver Policy can be found here.
\n\nAdded Value of Publishing with IntechOpen
\n\nChoosing to publish with IntechOpen ensures the following benefits:
\n\nBenefits of Publishing with IntechOpen
\n\n